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Abstract

THERAPEUTIC DRUGS IN CANCER AND RESISTANCE
By Aditi P. Martin, B.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2009
Major Director: Paul Dent
Professor, Department of Biochemistry and Molecular Biology

We investigated the mechanism of toxicity and resistance development of small molecule
tyrosine kinase inhibitor lapatinib in HCT 116 colon cancer cells. Lapatinib mediated cell
death in HCT 116 cells was caspase independent and involved cytosolic release of
apoptosis inducing factor. Treatment of HCT 116 cells with 10µM Lapatinib lead to the
outgrowth of lapatinib resistant HCT 116 cells. Our studies show that alterations in the
expression and activation of Bcl-2 family proteins allow lapatinib resistant HCT 116 cells
to resist cytotoxic effects of lapatinib as well as of other commonly used
chemotherapeutic agents.
In hepatoma and pancreatic cancer cells, the effects of combining multi-kinase inhibitor
sorafenib with histone deacetylase inhibitors (HDACIs) namely, vorinostat and sodium

xix

valproate were investigated. It was found that sorafenib synergizes with HDACIs
resulting in enhanced cell death compared to death induced by the drugs individually.
The mechanism of action of sorafenib and vorinostat combination treatment as well as
sorafenib and sodium valproate combined treatment was shown to involve activation of
the CD95 death receptor pathway. Alterations in the CD95 pathway can render cancer
cells resistant to chemotherapeutic agents. Hence, we combined sorafenib+sodium
valproate with a BH-3 domain mimetic named obatoclax (GX-15-070) which resulted in
enhanced toxicity to cancer cells. More importantly, knock-down of CD95 (to mimic
non-functional CD95 pathway) reduced cell death induced by sorafenib+sodium
valproate combined but failed to protect cells from cell death induced by
sorafenib+sodium valproate+obatoclax combined. This suggests that combining
sorafenib+HDACI with obatoclax may not only enhance toxicity to cancer cells but may
also reduce chances of resistance development via alterations in the CD95 pathway.
These studies enhance our knowledge of existing treatment strategies for cancer as well
as throw light on how current approaches can be improved in order to better diagnose and
treat cancer. Understanding mechanisms of drug action as well as resistance development
will allow us to combine existing therapies effectively in order best target cancer cells as
well as provide us with information that can help us design new cancer treatment
strategies.

1

GENERAL INTRODUCTION

A. Hallmarks of cancer:
Cancer is often defined as a disease involving uncontrolled division of abnormal cells.
Cancer is one of the leading causes of death, with one in eight deaths worldwide resulting
due to cancer (www.cancer.org(1)). In the United States, cancer is the second leading
cause of death and it is estimated that in 2009, 1500 people will die everyday as a result of
cancer (www.cancer.org(2)).
It is thought that a normal cell undergoes a series of changes in its genome that can
eventually lead to the generation of an aberrant cancer cell. Hanahan and Weinberg
identified six hallmarks of a cancer cell that are shared by most cancers (Hanahan D and
Weinberg RA, 2000).
1) No requirement for external growth signals
2) Insensitivity to anti-growth signals
3) Evasion of cell death signaling
4) Infinite potential to replicate
5) Ability to maintain oxygen and nutrient supply via angiogenesis
6) Ability to invade tissue and metastasize
There are a variety of growth factor receptors such as epidermal growth factor receptors
(EGFR), platelet-derived growth factor receptor (PDGFR), insulin-like growth factor-1
receptor (IGF-1R) and vascular endothelial growth factor receptor (VEGFR). Such
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receptors and their ligands as well as a variety of transcription factors and cell death
regulators are called oncogenes as mutant forms of these proteins or increased expression
of these proteins can lead to transformation of a normal cell into a cancerous cell (Croce
CM, 2008).
Normal healthy cells have growth factor receptors that are activated upon binding
stimulatory growth factors/ligands. Active receptors can mediate downstream signaling
that can stimulate cell growth and proliferation. There are no known normal cells that can
proliferate in the absence of such stimulatory signals (Hanahan D and Weinberg RA,
2000). However, cancer cells have been known to be able to proliferate independent of
such stimulatory signals. For instance, HCT 116 colon cancer cells are highly malignant
and are growth factor independent. HCT 116 cells have one mutant allele of KRas with a
Gly13Asp mutation. This mutation in KRas has been shown to be linked to up-regulation
of epiregulin (a pan-ERBB ligand) since loss of mutant KRas leads to reduction in levels
of epiregulin in HCT 116 cells (Yacoub A, et. al. 2006). This mutant KRas mediated upregulation of epiregulin has been shown to be invovled in promoting the tumorigenic
potential of HCT 116 cells (Baba I, et. al. 2000). Other studies have shown that upon
nutreint deprivation induced growth arrest, growth factor-dependent cells require both
nutrients and growth factors to recover from growth arrest, where as HCT 116 cells require
only nutrients to re-start DNA synthesis. This is because HCT 116 cells up-regulate
transforming growth factor-alpha (TGF-α) via enhanced transcription which can activate
EGFR and downstream pro-survival signaling even under growth arrest conditions. Hence,
HCT 116 cells have a TGF-α autocrine loop that can allow constitutive EGFR activation
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even under nutrient-deprivation and this allows them to be self sufficient in growth signals
(Awwad RA, et. al. 2003). Other cancer cells have also been shown to have increased
growth factor/ligand production due to altered gene expression resulting in an autocrine
loop and hence aberrant activation of growth factor receptors and downstream signaling
(Sizeland AM and Burgess AW. 1992).
Growth factor receptors belonging to the EGFR family are tyrosine kinases and play an
important role in cancer progression. They have been known to be over-expressed or
mutated such that they are constitutively active in a variety of cancers and this can lead to
increased activation of downstream pro-survival signaling resulting in aggressive cancer
(Peschard, P. and Park, M. 2003; Sunpaweravong, P. et. al. 2005; Hynes NE and Lane HA.
2005). These downstream pro-survival signaling pathways include the mitogen activated
protein kinase (MAPK) pathway and the phosphotidyl inositol-3 kinase pathway (PI3K)
(Grant S, et. al. 2002).
B. The MAPK pathway:
In order for MAPK signaling to occur downstream of EGFR activation, phosphorylated
tyrosine residues on active EGFR are recognised by Src homology 2 domain containing
scaffolding protein (SHC) which can hold growth factor receptor bound protein 2 (Grb2) in
association with a guanine nucleotide exchange factor called son of sevenless (SOS) via its
Src homoly 3 (SH3) domain. SOS assists activation of Ras protein (that is tethered to the
cell membrane via farnesylation or genranylgeranylation) by allowing Ras to release
guanosine diphosphate (GDP) in exchange for guanosine triphosphate (GTP) (Seabra MC.
1998). There are three types of Ras proteins known to date – Harvey Ras (HRas), Kirsten
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Ras (KRas), Neuroblastoma Ras (NRas) with KRas being the most frequently mutated Ras
isoform in cancer (Downward J. 2003). Active Ras is thought to recruit Raf protein, a
serine/threonine kinase also called a MAPkinase kinase kinase, to the cell surface. There
are three types of Raf proteins known to exist namely, c-Raf-1, B-Raf and A-Raf with BRaf being the most commonly mutated form (Sridhar SS, et. al. 2005; Davies H, et. al.
2002). Raf proteins exist in an inactive state, phosphorylated on certain residues and also
bound to 14-3-3 protein (Sridhar SS, et. al. 2005). The mechanism involving Raf activation
is not completely understood but it is thought that Ras-GTP is responsible for bringing Raf
protein to the cell surface and interacting with it to alter its conformation assisting in Raf
activation (Chong H, et. al. 2003). Some studies show that phosphatase enzymes such as
protein phosphatase 2 (PP2) are known to dephosphorylate Raf on certain residues and
allow it to be further phosphorylated on different residues by a Src family kinase rendering
Raf in an active state (Jaumot M and Hancock JF. 2001; Alavi A, et. al. 2003). Active Raf
can phosphorylate and activate mitogen-activated /extracellular-regulated protein kinase
(MEK), also called MAPkinase kinase, which is a dual specificity kinase that can
phosphorylate serine/threonine or tyrosine residues (Kyriakis JM, et. al. 1992; Dent P, et.
al. 1992). Active MEK1/2 can activate MAPK called extracellular signal regulated kinase
1/2 (ERK1/2) which is a serine/threonine kinase (Wu J, et. al. 1992). ERK1/2 can activate
various proteins such as Fos, Myc and Cyclin D-1 that can result in cells entering the cell
cycle (Birtwistle MR, et. al. 2007). ERK can phosphorylate and activate p90 ribosomal S6
kinase or p90rsk which can phosphorylate transcription factors involved in cell
proliferation (Amorino GP, et. al. 2002). ERK is also known to translocate into the nucleus
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where it can phsophorylate and activate a variety of other proteins such as Elk-1, STAT
proteins and the estrogen receptor (Whitmarsh AJ and Davis RJ. 1996; Adachi M, et. al.
2000). ERK can phosphorylate and inhibit activation of caspase 9 and pro-apoptotic
protein BAD (Allan LA, et. al. 2003; Scheid MP, et. al. 1999). The MAPK pathway can be
aberrantly activated in cancer due to alterations in the upstream receptors (Nair PN, et. al.
2001) or due to mutations in upstream Ras or Raf proteins rendering them constitutively
active (Bakin RE, et. al. 2003; Pfister S, et. al. 2008).
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Active receptor tyrosine kinase

RAS

PI3K

RAF

PDK1

MEK

AKT

ERK
PRO-SURVIVAL SIGNALING
Figure 1: The mitogen-activated protein kinase (MAPK) and the phosphotidyl
inositol-3 kinase (PI3K) pathway
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C. The p38 and JNK pathways:
There are other MAP kinases such as p38 and c-Jun N-terminal kinase (JNK) (Davis RJ.
2000). Four isoforms of p38 namely, α, β, γ and δ and three JNK proteins namely JNK 1, 2
and 3 are known to date (Alonso G, et. al. 2000; Waetzig V and Herdegen T. 2005). Upon
growth factor receptor activation, exposure to UV radiation, cytokines or mitogens, Ras
and Rho family GTPases can lead to p38 and or JNK activation downstream (Johnson GL
and Nakamura K. 2007). MEK 3 and MEK 6 can activate p38, MEK4 has been known to
activate p38 and JNK where as MEK 7 solely activates JNK (Johnson GL and Nakamura
K. 2007). Depending on cell type and stimulus, p38 and JNK signaling can promote cell
growth and survival or it can enhance cell death signaling (Lamb JA, et. al. 2003; Thorton
TM and Rincon M. 2009). For instance, depending on cell type and stimulus, p38
activation can influence either the progression of cell cycle transition by phosphorylation
of the retinoblastoma protein (pRb) or can lead to phosphorylation of the tumor suppressor
p53 (which is often called “guardian of the genome” and is discussed in detail later) which
can result in cell cycle arrest (Hoozemans JJ, et. al. 2004; Bulavin DV, et. al. 1999). p38
activation has also shown to lead to mitogen-activated protein kinase-activated protein
kinase 2 activation which can in turn activate HSP27. This pathway has been shown to be
invovled in cellular invasion in prostate cancer (Xu L, et. al. 2006).
It is thought that transient activation of JNK can mediate cell survival but prolonged
activation of JNK can lead to cell death (Chen YR, et. al. 1996). Also, studies from our
laboratory have shown that JNK isoforms may have variable functions. Treatment of
hepatocytes with deoxycholic acid lead to activation of JNK1/2 but it was found that under
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this treament condition, JNK1 signaling was cytotoxic where as JNK2 signaling was
cytoprotective (Qiao L, et. al. 2003).
Activated JNK can translocate to the mitochondria where it has been known to be involved
in the release of cytochrome c into the cytosol which is associated with activation of cell
death pathways (Tournier C, et. al. 2000). Upon activation, JNK can also translocate to the
nucleus and transactivate a variety of proteins including c-Jun, other transcription factors
and can also promote apoptosis by increase the expression of pro-apoptotic genes
(Dhanasekaran DN and Reddy EP). Reports show that in unstressed cells, JNK can lead to
p53 ubiquitination and degradation (Fuchs SY, et. al. 1998). However, under certain
stressful situations (such as upon DNA damage), JNK can phosphorylate and stabilize p53,
preventing its degradation, and allowing p53 to initiate cell cycle arrest or cell death
pathways (BuschmannT, et. al. 2001). Active JNK can phosphorylate pro-apoptotic protein
BAD and allow this protein to engage in apoptotic signaling (Donovan N, et. al. 2002).
The role of JNK in cell death pathways is consistent with JNK having a tumor suppressive
role (Kennedy NJ and Davis RJ. 2003). However, other studies show that JNK has a
preferential role in proliferation since JNK deficient mice were resistant to the induction of
papillomas (Chen N., et. al. 2001). Secondly, it has been shown that mice harboring
prostate cancer cells when treated with antisense JNK1 and JNK2 inhibited tumor growth
and lead to significant tumor regression (Yang YM, et. al. 2003). Other reports show that
JNK signaling is involved in the malignant transformation of osteoblasts and in the
progression of osteosarcomas (Papachristou DJ, et. al. 2003). Hence, JNK is often thought
to have a pro-oncogenic role.
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Figure 2: p38 and JNK signaling pathways.
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D. The PI3K pathway:
The PI3K pathway can also mediate pro-survival signaling. PI3K is a dimer consisting of a
p85 regulatory subunit and a p110 catalytic subunit (Cantley LC. 2002). Activation of
receptor tyrosine kinases can recruit PI3K directly or via adaptor molecules (SHC-GRb2SOS complex) (Cantley LC. 2002). PI3K can then phosphorylate phosphotidylinositol
bisphosphate (PIP2) to generate phosphotidylinositol trisphosphate (PIP3). PIP3 in turn
can recruit signaling proteins with pleckstrin homology domain (PH domain) such as
serine threonine kinases phosphoinositol-dependent kinase-1 (PDK-1) and Akt (also called
protein kinase B) to the membrane (Luo J, et.al. 2003). This brings Akt and PDK1 in close
proximity allowing them to interact resulting in PDK1 mediated Akt phosphorylation and
activation (Lawlor MA and Alessi DR. 2001). Active Akt can then regulate a variety of
proteins that control cell proliferation, survival, growth and other processes. For instance,
Akt can inhibit the function of death-inducing proteins such as BAD and p53 and it can
regulate cell cycle by stabilizing cyclin-D (Luo J, et.al. 2003). There are three known
mammalian isoforms of Akt namely, Akt 1, 2 and 3 that are generated from distinct genes
(Franke TF. 2008). Reports suggest that these isoforms of Akt have diverse functions (Bae
SS, et. al. 2003; Jiang ZY, et. al. 2003). PTEN, a tumor suppressor and a negative
regulator of the PI3K-Akt pathway can dephosphorylate PIP3 and convert it back to PIP2
(Cantley LC and Neel BG. 1999). Certain cancers have been shown to have mutant PTEN
such that it can no longer inhibit the PI3K pathway and thereby allow constant activation
of this pro-survival pathway (Maehama T and Dixon JE. 1999). Other oncogenic changes
that can lead to hyperactivity of the PI3K-Akt pathway are alterations in growth factor
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receptors and Ras which are both upstream of Akt. Hyperactivity of the Akt pathway is
regarded as a negative prognostic marker for disease outcome in cancer patients
(LoPiccolo J, et. al. 2008). A mutation in the PH domain of Akt1 has also been associated
with increased plasma membrane recruitment and activation of the kinase and its
downstream pathways (Bleeker FE, et. al. 2008). Hence, the PI3K/Akt pathway has been a
prime target in developing therapies to treat cancer.
E. The tumor suppressor p53:
As mentioned previously, p53 is often referred to as the “guardian of the genome”. Murine
double minute 2 or MDM2 (HDM2 in humans) protein maintains p53 at low levels in
normal, unstressed cells by ubiqitinating p53 and targeting it for degradation by the
proteasome (Kubbuttat MH, et. al. 1997). Post translational modifications of p53 such as
acetylation, phosphorylation and methylation also play a role in stabilizing and activating
p53 under stressful situations (Moll UM and Petrenko O. 2003). Several stimuli such as
hypoxia and DNA damage can activate enzymes such as ATM and ATR that can
phosphorylate p53 thereby increasing its stability and transcriptional ability (Graeber TG,
et. al. 1994; Siliciano JD, et. al. 1997). These enzymes can also rapidly increase p53 levels
via phosphorylation of MDM2 that prevents it from interacting with p53 (Maya R, et. al.
2001; Shinozaki T, et. al. 2003). p53 activation can in turn lead to increase in ARF protein
levels which can interact with MDM2 and inhibit its p53-ubiqutin ligase activity there by
allowing p53 to stabilize (Palmero I, et. al. 1998). On the other hand, p53 activation can
increase transcription of the gene encoding for MDM2 which will eventually lead to
inhibiton of p53 forming a negative feedback loop (Wagner J, et. al. 2005). In several
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cancers with wild type p53, the MDM2 gene has been shown to be amplified (Oliner JD,
et. al. 1992). Hence, in spite of bearing wild-type p53, the amplified MDM2 expression
may prevent appropriate activation of p53 upon toxic insult to these cells thereby allowing
them to evade cell death. In certain cancers, mutations or epigenetic alterations in the gene
encoding for ARF have been noted which could also result in lack of appropriate p53
response to prevent unwarranted cell growth and proliferation (Saporita AJ, et. al. 2007).
Above mentioned alterations in MDM2 and ARF function can prevent appropriate p53
activation there by assisting cancer cells in evading cell death pathways.
Failure to arrest cell cycle progression can allow a cell with damaged DNA to replicate.
p53 is known to regulate cell cycle check points in order to maintain the genetic stability of
cells. Active p53 is known to mediate cell cycle arrest by inducing the transcription of p21
which is a cyclin dependent kinase inhibitor (Miyashita T and Reed JC. 1995). Once
active, p53 is also known to lead to the transcription of a variety of genes that encode
proteins involved in cell death pathways such as BAX, Fas, Noxa, Puma, Caspase 1 and 6,
Apaf-1, etc. These genes are expressed to similar levels during p53 mediated G1 arrest and
apoptosis (Attardi LD, et. al. 2000). Depending on cell type and stimuli, activation of p53
can result in not only apoptosis or cell cycle arrest but also in induction of differentiation
or senescence (Vousden KH and Lu X. 2002). p53 mediated effects can also occur
independent of its transcription activity. In the presence of stress, p53 is thought to initiate
cell death pathways by translocating to mitochondria resulting in loss of mitochondrial
membrane potential and activation of the caspase cascade (Marchenko ND, et.al. 2000;
Nemajerova A, et.al. 2005). Reports suggest that mitochondrial migration of p53 has a
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more important role to play in p53 mediated cell death than cell cycle arrest. Studies show
that translocation of p53 to the mitochondria after exposure to stress occurs in cells that
undergo cell death but not in cells that undergo cell cycle arrest (Marchenko ND, et.al.
2000; Erster S, et. al. 2004). About 50% of cancers lack p53 protein expression, bear
mutant or inactive p53 (Toledo F and Wahl GM. 2006). Mutation in p53 in germ line cells
has also been implicated in Li-Fraumeni syndrome making patients prone to a variety of
cancers (Senzer N, et. al. 2007). Mutant p53 can play an important role in the
transformation of normal cells to cancerous cells and it is also known that tumors bearing
wild type p53 are more sensitive to chemotherapy than tumors bearing mutant p53 (Wang
W and El-Deiry WS. 2008). Most p53 mutations in cancer cells are missense mutations
that occur in its DNA binding domain, precluding p53 from binding to its response
elements on DNA and therefore preventing transcription of p53 target genes (Strano S, et.
al. 2007; Hussain SP and Harris CC. 1998; Prives C and Hall PA. 1999). p53 bears a
tetramerization domain and upon activation, this domain allows p53 proteins to tetramerize
which is essential for p53 function, enabling p53 to bind DNA and transcribe genes. In
cancer cells, mutations have been noted in the tetramerization domain of p53 that can
prevent wild type p53 function by inhibiting p53 tetramer formation (Chène P. 2001).
Mutations in tumor suppressor genes are recessive in nature and hence, in order for a cell
to become cancerous, both alleles of the tumor suppressor gene need to be mutated. This
theory is called “Knudson’s two hit hypothesis” and was suggested by Dr. Alfred Knudson
in 1971 (Knudson A. 1971). p53 is an exception to this rule since mutant p53 can exert a
“dominant negative” effect such that mutant p53 can inhibit the function of wild type p53
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generated from the un-mutated allele by forming non-functional p53 tetramers that can not
transcribe genes succesfully (Blagosklonny MV. 2000).
Studies have also shown that certain cancer cells have p53 protein with gain of function
mutations that allow mutant p53 to exert functions that the wild type protein can not. These
mutants may not only behave as dominant negative mutants to inhibit wild type p53
function but also provide a growth and survival advantage to the cancer cell as they have
been implicated in increasing expression of genes such as the multi drug resistance gene
which can prove to be very beneficial for cancer cells by allowing them to pump out toxic
drugs from their systems (van Oijen M and Slootweg PJ. 2000; Chin KV, et. al. 1992).
Cancers bearing a gain of function mutation in p53 indicate poorer prognosis than cancers
with no p53 protein at all (Dittmer D, et. al. 1993).
F. Cell death pathways:
As discussed previously, the presence of cellular stress can lead to activation of cell death
pathways. There are various types of cell death pathways such as autophagy, apoptosis and
necrosis. Attempts have been made to reach a consensus on the criteria used to
differentiate between these forms of death but have been unsuccessful partially due to
overlaps in characteristics observed in these form of cell death (Krantic S, et. al. 2007).
Autophagy (derived from Greek, “auto” meaning self and “phagy” meaning to eat) is a
form of programmed cell death (Yorimitsu T and Klionsky DJ. 2005; Clarke PG. 1990).
Autophagy has a role in protein degradation and cellular turnover and is characterized by
sequestration of the cytosol and organelles in a multi-membrane vesicle which is then
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degraded by the lysosomal system (Gozuacik D, Kimchi A. 2004). Autophagy usually
occurs at a low basal level and is often upregulated during events such as starvation when
the nutrient demands of a cell are not met (Kourtis N and Tavernarakis N. 2009). In such
situations, autophagy can allow degradation of cytoplasmic components of a cell, there by
providing the nutrient deprived cell with substrates for energy metabolism and protein
synthesis in order to survive. However, there is an ongoing debate regarding the role of
autophagy since it has not only been observed to be involved in survival processes but it
has also been known to cause cell death (Levine B and Klionsky DJ. 2004; Shintani T and
Klionsky DJ. 2004; Wang CW and Klionsky DJ. 2003; Bursch W. 2004).
Apoptosis is a type of programmed cell death and cells undergoing apoptosis have a very
characteristic morphology that includes membrane blebbing, cell shrinkage, chromatin
condensation, nuclear and DNA fragmentation (Savill J, et. al. 2003). Necrosis is an unprogrammed form of cell death that occurs due to external insults on a cell or due to nonphysiological attacks such as ischemia, hypothermia or hypoxia (de Bruin EC and Medema
JP. 2008). Necrosis is characterized by loss of membrane integrity, swelling of
mitochondria and the cell itself resulting in cell lysis (de Bruin EC and Medema JP. 2008).
It is generally accepted that necrosis is a process that does not require energy where as
apoptosis is an ATP-dependent process (Leist M, et. al. 1997). Another difference between
apoptosis and necrosis is that apoptosis occurs in individual cells whereas necrosis occurs
in contiguous cells and also generates an immune response which is absent in apoptotic
cell death (Vakkila J and Lotze MT. 2004).
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Extrinsic and intrinsic death pathways are apoptotic cascades that can be activated by
several chemotherapeutic agents. The extrinsic cell death pathway involves activation of
death receptors that are members of the tumor necrosis factor receptor superfamily, known
to regulate cell death and survival (Ashkenazi A. 2002). One of the best characterized
death receptor is CD95, also called Fas or APO-1 receptor, which binds to CD95/Fas
ligand (CD95L/FasL) (Walczak H and Krammer PH. 2000). Upon ligand binding, CD95
death receptors can trimerizes and recruit adaptor molecules such as the Fas associated
death domain (FADD) (Walczak H and Krammer PH. 2000). FADD can then recruit procaspase 8 or pro-caspase 10 to the death receptor which leads to the formation of the death
inducing signaling complex or DISC (Kischkel FC, et. al. 1995). Caspases are cystein
proteases, synthesized as pro-enzymes and cleaved next to aspartate residues for activation
after which they can act as death effector molecules for several cell death pathways
(Degterev A, et. al. 2003). Once recruited by FADD to the death receptors, pro-caspases
can become activated by undergoing cleavage and can further activate downstream
caspases resulting in amplification of the caspase cascade (Degterev A, et. al. 2003;
Scaffidi C, et. al. 1998). Once caspases are activated, they can lead to cleavage of various
cytosolic and nuclear substrates such as cytoskeletal proteins and nuclear lamins that can
lead to loss of cell shape and result in shrinking of the nucleus, respectively (Degterev A,
et. al. 2003). Active caspases can also cleave the inhibitor of caspase activated DNAse
(ICAD) leading to polynucleosomal DNA fragmentation resulting in the characteristic
oligomeric DNA fragments seen upon caspase activation (Nagata S. 2000). Similar to
various other signaling pathways, the extrinsic cell death pathway also can be negatively
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regulated by FLIP proteins. There are several splice variants of FLIP known to exist at the
mRNA levels but only three isoforms of FLIP protein namely, c-FLIP-s, c-FLIP-r and cFLIP-l have been identified (Djerbi M, et. al. 2001; Rasper DM, et. al. 1998; Golks A, et.
al. 2005). Studies have suggested similar roles of c-FLIP-s and c-FLIP-r in death receptor
mediated apoptosis (Golks A, et. al. 2005). c-FLIP-s plays an anti-apoptotic role as it can
inhibit the activation of pro-caspase 8 and there by inhibit CD95 induced cell death (Golks
A, et. al. 2005). These FLIP proteins have sequence homology to caspase 8 but lack their
catalytic domain and hence when FLIP is recruited to activated death receptors, it can
block activation of the caspase cascade and the cell death cascade (Krueger A, et. al.
2001). However, the role of c-FLIP-l in the activation of CD95 pathway remains
controversial. Some studies suggest the c-FLIP-l is an anti-apoptotic molecule where as
other studies ascribe pro-apoptotic functions to c-FLIP-l referring to its assistance in procaspase 8 activation (Chang DW, et. al. 2003; Micheau O, et. al. 2002).
Death receptors play an important role in immunity. T-cells can regulate the immune
system via production of CD95L which can trigger cell death in neighboring target cells
such as lymphocytes by activating the CD95 receptors in these cells (Krammer PH. 2000).
However, if the T-cells secrete CD95L resulting in soluble CD95L, this can activate CD95
receptors on their own cell membrane and can lead to their death (Klas C, et. al. 1993).
Reports suggest that some cancers express CD95L but lose CD95 receptor expression. This
can allow them to evade attack from host immune cells by killing tumor-attacking T-cells
via activation of the CD95 receptors on these cells (Muschen M, et. al. 2000). Studies have
shown that certain cancer cells that do express CD95 receptors can also evade attacks from
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host immune cells by expressing soluble decoy receptor 3 (DcR3), known to compete with
CD95 receptor for CD95L, thereby interfering with CD95 mediated cell death activation in
cancer cells (Roth W, et. al. 2001). Down-regulation or absence of surface CD95 receptor
expression in cancer cells can occur via epigenetic changes such as hypermethylation of
gene promoters and can play an important role is mediating resistance to chemotherapeutic
agents that require CD95 receptors to induce their toxic effects (van Noesel MM, et. al.
2002; Friesen C, et. al. 1997). It has been suggested that the CD95 death receptor system
has a tumor suppressive function due to the occurrence of CD95 receptor mutations in
cancers (Fulda S and Debatin KM. 2006). Elevated FLIP expression has also been found in
cancer cells that can render them resistant to chemotherapeutic agents requiring activation
of the extrinsic cell death pathway to mediate their toxic effects (Longley DB, et. al. 2006).
Activation of the intrinsic cell death pathway depends on the balance between pro-death
and pro-survival Bcl-2 family proteins. The Bcl-2 family proteins have upto four Bcl-2
homology (BH) domains (BH1, BH2, BH3 or BH4) (Yip KW and Reed JC. 2008). The
pro-survival Bcl-2 proteins (such as Bcl-xl, Mcl-1, Bcl-2, etc.) have all four BH domains
where as the pro-death members can be further divided into two classes: the “multidomain” proteins that have BH1, BH2 and BH3 domains (such as Bax, Bak and Bok) and
the “BH3 only proteins” that, as the name suggests, bear only the BH3 domain (such as
Bid, Bim, Bad, Puma, Noxa) (Yip KW and Reed JC. 2008; Reed JC. 2006; Strasser A.
2005). Bcl-2 family members are known to interact with each other via the BH3 domain
(Chittenden T, et. al. 1995).
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The “BH3 only” proteins can interfere with the actions of pro-survival Bcl-2 family
proteins and on the other hand, can also interact with Bak and Bax leading to their
activation (A. Letai et. al. 2002). Studies suggest that oligomerization of pro-death
members of the Bcl-2 family such as Bak and Bax can activate the intrinsic cell death
pathway by forming pores in the outer mitochondrial membrane leading to mitochondrial
outer membrane permeabilization (MOMP) (Chipuk JE and Green DR. 2008; Green DR
and Kroemer G. 2004). Cells obtained from mice that do not express Bak and Bax fail to
undergo cell death in response to insults that would typically lead to death in cells that
express these proteins (Wei MC, et. al. 2001). Loss of mitochondrial membrane potential
and MOMP can lead to release of various proteins from the inter-membrane space of the
mitochondria that can induce cell death. These include proteins that can activate caspases
(e.g. cytochrome c), proteins that can interfere with the function of caspase inhibitors (e.g.
SMAC and Omi/Htra2 known to interfere with inhibitors of apoptosis or IAPs) and also
proteins that are thought to cause cell death independent of caspase activation (e.g.
apoptosis inducing factor and endonuclease G that can make their way to the nucleus
where they can lead to DNA degradation) (Penninger JM and Kroemer G. 2003; Reed JC.
2002). Cytochrome c release from the mitochondria can lead to caspase activation via
formation of the apoptosome which consists of cytochrome c, apoptotic protease activating
factor 1 (Apaf-1) and pro-caspase 9 (Cain K, et. al. 2000). Binding of cytochrome c to
Apaf-1 is thought to facilitate ATP binding to the apoptosome which then allows for
caspase 9 activation (Adrain C, et. al. 1999). Active caspase 9 can lead to activation of
various other caspases including caspase 2, 3, 6, 7, 8 and 10 (Guerrero AD, et. al. 2008). It
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is important to note that the extrinsic and intrinsic cell death pathways can crosstalk. As
mentioned earlier, activated death receptors can lead to caspase 8 activation. Active
caspase 8 can cleave Bid (a “BH3 only” protein) which can translocate to the mitochondria
and interfere with the pro-survival functions of Bcl-xl and is also thought to play a role in
assisting in oligomerization of Bak and/or Bax that leads to pore formation in the
mitochondrial membrane and MOMP (Gross A, et. al. 1999; Korsmeyer SJ, et. al. 2000).
Disruption of the intrinsic cell death pathway has been observed in cancer. For instance,
over-expression of pro-survival Bcl-2 family proteins can promote oncogenesis (Tsujimoto
Y, et. al. 1984; Fulda S and Debatin KM. 2006). Defects in the expression of pro-death
Bcl-2 family members can also occur in cancer cells. Homozygous deletions and
inactivating mutations have been identified in genes encoding for pro-death Bcl-2 family
proteins in cancer cells which can prevent activation of cell death pathways and hence
prove beneficial for cancer cell survival (Meijerink JP, et. al. 1998).
G. Chemotherapeutic agents:
The above mentioned pathways and proteins can play an important role in tumor
development and progression. Hence, drugs have been developed to target them in order to
treat cancer. As mentioned previously, receptor tyrosine kinases such as EGFR have been
implicated in cancer progression as they have been found to be mutated such that they are
constitutively activated or over-expressed in cancer (Peschard, P. and Park, M. 2003;
Sunpaweravong P, et. al. 2005). Hence, several drugs have been developed to target these
kinases. The development of small molecule tyrosine kinase inhibitors (TKIs) targeting
EGFR family members was based on the observation that mutations in the ATP-binding
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site affected receptor kinase function severely (Honegger AM, et. al. 1987). TKIs prevent
ATP binding on the internal kinase domain of EGFR therefore preventing phosphorylation
of key tyrosine residues which is an essential step in receptor activation (Imai K and
Takaoka A. 2006). Gefitinib and erlotinib are two TKIs that inhibit ERBB1 receptors
(Janne PA. 2008). Lapatinib was developed to target both ERBB1 and ERBB2 receptors of
the EGFR family and targeting two tyrosine kinases is advantageous as it can be used to
treat cancers that over-express ERBB1 and/or ERBB2 and also reduces the chances of
resistance development in cancer cells (Yarden Y and Sliwkowski MX. 2001). Several
monoclonal antibodies have been developed that recognize and bind to the extracellular
domain of receptor tyrosine kinases thereby preventing ligand binding and downstream
signaling (Rowinsky EK. 2004). Binding of monoclonal antibodies to receptors can
induces dimerization and internalization of the receptor, eventually leading to receptor
degradation and downregulation (Mendelsohn J. 2002). Herceptin/Trastuzumab is a
monoclonal antibody that inhibits ERBB2 activation and has proven to be quite successful
in treating breast cancers that frequently over-express ERBB2 receptors (Bange J, et. al.
2001).
In solid tumors, hypoxia can induce the release of vascular endothelial growth factor
(VEGF) by tumor cells and by regions around the tumor called stroma (Das B, et. al.
2005). VEGF can bind to its receptors (that are also tyrosine kinases) and can stimulate
angiogenesis (Parikh AA and Ellis LM. 2004). Hence, VEGF inhibitors were developed to
inhibit the remodelling of the network of blood vessels required by certain solid tumors for
growth and survival. Some VEGFR inhibitors are: semaxinib, vatalinib and sutent.
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Platelet derived growth factor receptors (PDGFR) are also receptor tyrosine kinases that
have been implicated in cancer progression as they can mediate downstream pathways that
can regulate cellular growth and proliferation (Sedlacek HH. 2000). PDGFR has been
implicated in cellular transformation and has been found to be over-expressed in a variety
of cancer cells (Sedlacek HH. 2000). Leflunomide is a PDGFR inhibitor that was
developed to inhibit PDGFR mediated signalling in cancer cells (Shawver LK, et. al.1997).
As mentioned previously, alterations in Ras oncogene have been implicated in cancer
progression (Downward J. 2003). Ras is tethered to cell membranes via farnesylation or
geranylgeranylation (Seabra MC. 1998). Hence, inhibitors of farnesyl transferase (e.g. FTI277) and geranylgeranyl transferase-1 (e.g. GGTI-298) have been developed to prevent the
prenylation of Ras protein which is required for its activity (Der CJ and Cox AD. 1991).
Active Raf, which is downstream of Ras, can mediate pro-survival signaling and has been
frequently observed to be mutated in cancer cells (Davies H, et. al. 2002). Hence Raf
kinase inhibitors such as sorafenib have been developed. However, it is now known that
sorafenib can inhibit Raf as well as a variety of other kinases including VEGFR and
PDGFR (Strumberg D, et. al. 2005).
In tumor cells, over-expression of MDM2 can inhibit wild-type p53 activation protecting
cancer cells from toxic effects of chemotherapeutic agents (Oliner JD, et. al. 1992). Hence,
drugs such as Nutlins have been developed that can mimic p53 and thereby bind MDM2
(Vassilev LT. 2005). Nutlins can therefore inhibit p53-MDM2 interaction and allowing
appropriate activation of the p53 pathway in cancer cells leading to cell cycle arrest, cell
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death and also growth inhibition of tumor cells in human tumor xenograft models
(Vassilev LT, et. al. 2004).
Histone deacetylase inhibitors (HDACI) are another family of chemotherapeutic agents
that are thought to inhibit tumor survival and growth by regulating expression of several
genes involved in proliferation and/or apoptosis (Peart MJ, et. al. 2005). Histone
deacetylase inhibitors (HDACI) represent a class of agents that act by blocking histone deacetylation, thereby modifying chromatin structure and gene transcription. HDAC
inhibitors (HDACIs) promote histone acetylation and neutralization of positively charged
lysine residues on histone tails, allowing chromatin to assume a more open conformation,
which favors transcription (Gregory PD, et. al. 2001). However, HDACIs are known to
promote acetylation of non-histone proteins as well (Dasmahapatra G, et. al. 2007; Marks
PA, et. al. 2003; Bali P, et. al. 2005; Kwon SH, et. al. 2002). Most HDACIs are thought to
function by binding to the zinc atom in the HDAC catalytic site thereby inhibiting the
enzyme’s activity (Richon VM. 2006; Taddei A, et. al. 2005). HDACI such as vorinostat
and sodium valproate are known to cause up-regulation of pro-apoptotic genes, downregulation of anti-apoptotic genes, growth arrest, differentiation as well as cell death in a
variety of cancer cells (Mitsiades CS, et. al. 2004; Richon VM, et. al. 1998; Kuendgen A,
et. al. 2007).
Certain cancer cells have been shown to be highly dependent on over-expression of prosurvival Bcl-2 family proteins in order to evade death signals induced by chemotherapeutic
agents (Tsujimoto Y, et. al. 1984). Hence, BH-3 mimetics were developed that mimic the
BH-3 domain of the pro-death Bcl-2 family members and interact with pro-survival Bcl-2
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members there by inhibiting their function (Zhang L, et. al. 2007). One such agent is ABT737 that has a high affinity for binding Bcl-xl, Bcl-2 and Bcl-w but since it is unable to
effectively inhibit Mcl-1, several cancer cells have been shown to be resistant to this agent
(van Delft MF, et. al. 2006). Another BH-3 mimetic is -(-) Gossypol that is known to
inhibit Bcl-2, Bcl-xl and Mcl-1 and is currently in Phase II clinical trials for treatment of
prostate cancer (Meng Y, et. al. 2008). Gossypol can induce a conformational change in
Bcl-2 and Bcl-xl proteins thereby converting their pro-survival function to pro-death
resulting in cytochrome c release from the mitochondria that can induce cell death
pathways (Lei X, et. al. 2006). Obatoclax is another such BH-3 mimetic that is currently in
Phase II clinical trials being investigated both as a single agent and in combination with
other drugs (www.geminx.com).
Hence, new molecular targets are being discovered and novel drugs as well as drug
combinations are being identified that may enhance our ability to treat as well as prevent
resistance development in cancer.

.

.
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MECHANISM OF LAPATINIB TOXICITY AND RESISTANCE IN HCT 116
CELLS
A. Introduction:
The EGFR family consists of four members, namely ERBB1, ERBB2, ERBB3 and
ERBB4 (Olayioye, et. al. 2000; Yarden Y and Sliwkowski MX. 2001). These receptors are
present on the cell surface as monomers and upon ligand binding, can homo- or heterodimerize thereby increasing their affinity for ATP binding which allows
autophosphorylation of specific tyrosine residues on the cytosolic domain of the receptors
that serve as docking sites for molecules which can mediate downstream intracellular
signaling (Hynes NE and Lane HA. 2005; Lin NU and Winer EP. 2004; Nelson MH and
Dolder CR. 2006). A variety of cancers have been shown to have deregulated EGFR
signaling via various mechanisms such as constitutive receptor activation, impaired
receptor down-regulation and increased receptor stimulation via an autocrine loop leading
to constitutive downstream pro-survival signaling resulting in very aggressive tumors
(Peschard, P. and Park, M. 2003; Sizeland AM and Burgess AW. 1992; Sunpaweravong P,
et. al. 2005; Salomon, DS, et. al. 1995; Hynes NE and Lane HA. 2005). Hence, studies
have been performed to identify mechanisms via which ERBB receptors and their
downstream signaling pathways can be inhibited in such tumor cells. Current strategies
aimed at inhibiting receptor activation include (i) monoclonal antibodies that prevent
ligand binding to the receptors (example: cetuximab), (ii) quinazoline-derived small
molecule tyrosine kinase inhibitors (TKIs) that prevent ATP binding in the kinase domain
of the receptors thereby inhibiting receptor kinase activity required to activate downstream
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signaling (example: lapatinib, erlotinib) and (iii) dominant negative ERBB1 and ERBB2
receptors (CD533 and CD572, respectively) that have truncated C-terminal kinase
domains, hence forming non-functional dimers with wild type receptors (Imai K and
Takaoka A. 2006; Schmidt-Ullrich RK, et. al. 2003).
Lapatinib is a reversible small molecule TKI developed by GlaxoSmithKline that can
efficiently inhibit ERBB1 and ERBB2 activation. IC50 values for purified ERBB1 and
ERBB2 inhibition via lapatinib are 10.2 and 9.8 nM, respectively (Wood ER, et. al. 2004;
Rusnak DW, et. al. 2001). Several studies show lapatinib to be a promising therapeutic
agent for treating cancer. Lapatinib (Tykerb) was recently approved by the Food and Drug
Administration to be used in combination with capecitabine to treat patients with advanced
or metastatic breast cancer that over-express ERBB2 and have been previously treated with
other drugs (National Cancer Institute). Lapatinib has been studied in
herceptin/trastuzumab resistant breast cancer lines and has been shown to induce apoptosis
in such cells by inhibiting downstream pro-survival signaling mediated by ERBB1,
ERBB2 and also insulin like growth factor –1 receptor (IGF-1R) (Nahta R, et. al. 2007).
Bcl-2 is an anti-apoptotic protein that has been shown to be over-expressed in certain
cancer cells and associated with drug resistance by allowing cells to evade death signals
(Reed JC, et. al. 1996; McDonnell TJ, et. al. 1992). Combination studies involving
lapatinib and Bcl-2 inhibitors in certain cancer cells show synergistic anti-tumor effects
(Witters LM, et. al. 2007). Lapatinib is >300 fold selective for ERBB1 and ERBB2
inhibition compared to its ability to inhibit other kinases commonly found in a cell
(Rusnak DW, et. al. 2001). This high selectivity may prevent undesirable effects arising
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from non-specific inhibition of other molecules by lapatinib. Lapatinib is a particularly
efficacious anti-cancer agent because it can inhibit two ERBB receptors simultaneously.
This may allow lapatinib to be used to treat a wide variety of cancers that may depend on
ERBB1 and/or ERBB2 signaling and also reduce the chances of resistance development in
cancer cells.
Usually, cancer patients treated with chemotherapeutic agents respond well initially
resulting in the reduction of tumor size and death of cancer cells. However, months or
years later, the cancer can reappear as an aggressive and therapeutically refractory
malignancy that may be cross-resistant to many other therapeutic drug treatments, making
such refractory cancers very difficult to manage (Kobayashi S, et. al. 2005). There are
several ways in which a cancer cell can become resistant to chemotherapeutic agents.
Resistance to trastuzumab has been suggested to be mediated via the insulin like growth
factor –1 receptor (IGF-1R) signaling that can activate downstream pro-survival pathways
(Lu Y, et. al. 2001; Camirand A, et. al. 2002). Src (a tyrosine kinase) and estrogen receptor
have also been implicated in mediating resistance to TKIs in certain cancer cells by
activating pro-survival signaling pathways (Qin B, et. al. 2006; Xia W, et. al. 2006).
Resistance to ERBB targeted drugs can also occur due to mutations in ERBB receptors
resulting in the inability of drug to inhibit receptor activation (Pao W, et. al. 2005; Sok JC,
et. al. 2006). Multi-drug resistance pumps may also be involved in drug resistance by
pumping out toxic drugs from cancer cells (Szakacs G, et. al. 2006). As mentioned
previously, studies have also shown that certain cancer cells over-express anti-apoptotic
molecules belonging to the Bcl-2 family which can protect these cells from cyto-toxic
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effects of drugs by allowing them to evade cell death signals and hence render them
resistant to chemotherapeutic agents (Raffo AJ, et. al. 1995).
Constitutive activity of the transcription factor nuclear factor κB (NF-κB) has also been
implicated in drug resistance (Herrmann JL, et. al. 1997; Sumitomo M, et. al. 1999).
Inhibitor of κB (IκB) usually sequesters NF-κB in the cytosol. IκB Kinase (IKK) can
phosphorylate IκB leading to its degradation. This releases NF-κB which can then
translocate to the nucleus where it can initiate transcription of genes involved in survival
(Baldwin AS. 2001). In certain cancer cells, constitutive NF-κB activation due to defective
IκB activity or persistent IKK activity, allows constant transcription of genes involved in
cellular growth (Cabannes E, et. al. 1999; Kordes U, et. al. 2000).
Resistance to the effects of lapatinib has been demonstrated in BT474 breast cancer cells
and was reported to occur via estrogen receptor signaling (Xia W, et. al. 2006). As noted
by the authors, a combination of lapatinib and estrogen receptor inhibitors may decrease
the probability of development of refractory cancers and therefore enhance the chances of
patient survival. Lapatinib has not been approved for the treatment of colon cancer yet,
although its potential effectiveness has been reported. Various colon cancer cell lines have
been reported to express ERBB1 and ERBB2 receptors, including HCT116 cells and
lapatinib has been shown to cause inhibition of cell proliferation and apoptosis in vitro and
in vivo in cancer cells of this origin (Cunningham MP, et. al. 2006; Zhou Y, et. al. 2006).
We have generated lapatinib resistant HCT 116 colon cancer cells and the aim of this
project was to understand the mechanism of action of lapatinib as well as lapatinib
resistance in HCT116 colon cancer cells. Understanding drug resistance may enable us to
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reduce the chances of occurrence of refractory cancers by targeting the pathways utilized
by resistant cells for survival and increase the likelihood of patient survival.
B. Materials:
Dulbecco's modified Eagle's medium, penicillin/streptomycin, and 0.25% trypsin-EDTA
were purchased from Invitrogen (Carlsbad, CA). HCT116 cells were originally purchased
from American Type Culture Collection (Manassas, VA) before multiple transfection
procedures. Fetal bovine serum was purchased from Hyclone (Logan, UT). Trypan blue
dye and crystal violet for colony-formation assays were purchased from Sigma-Aldrich (St.
Louis, MO). For Western blot analysis, 8 to 16% Tris-HCl gels were used (Bio-Rad
Laboratories, Hercules, CA). CMV control virus, ERBB1-CD533, and ERBB2-CD572
were obtained from Dr. Kristoffer Valerie (Virginia Commonwealth University,
Richmond, VA). BCL-XL recombinant adenovirus was obtained from Dr. J. Moltken
(University of Cincinnati, Cincinnati, OH). Dominant-negative (dn) dnI B (S32A)
recombinant adenovirus and STAT inhibitory peptide were purchased from Cell Biolabs
(Philadelphia, PA) and Calbiochem, respectively. Control siRNA and siRNA to
knockdown apoptosis-inducing factor (AIF) (SI02662114, SI02662653), Bcl-xl
(SI03025141, SI03068352, SI03112018, SI00023191), Mcl-1 (SI02781205, SI00131768),
and BAK (SI00299376, SI02654512) were purchased from QIAGEN (Valencia, CA).
Lapatinib was obtained from GlaxoSmithKline (Boston, MA). The IGF-1R inhibitor PPP,
the Src family kinase inhibitor PP2, 4-hydroxy tamoxifen, and epidermal growth factor
were purchased from Calbiochem (San Diego, CA). Primary antibodies against Mcl-1, Bclxl, BAX, BAK, AIF, and cytochrome c were purchased from Cell Signaling Technology
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Inc. (Danvers, MA). ERBB1 (Ab-5) antibody for fluorescence microscopy, primary
antibody for active BAK (Ab-1), caspase 8 inhibitor LEHD, caspase 9 inhibitor IETD, and
pan-caspase inhibitor zVAD were purchased from Calbiochem. EGF receptor (Ab-13
cocktail) and c-ERBB2 (Ab-11 cocktail) to immunoprecipitate ERBB1 and ERBB2 were
purchased from NeoMarkers (Freemont, CA). Anti-Phospho-Tyr 4G10 antibody was
purchased from Millipore Bioscience Research Reagents (Temecula, CA). Primary
antibodies for GAPDH, wild-type p53 (FL-393), mutant p53 (Pab 240), ERK2, active BAX
(6A7), and protein A/G Plus agarose beads for immunoprecipitation were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Secondary mouse antibody (Alexa Fluor 680
goat anti-mouse IgG) was purchased from Invitrogen, and secondary rabbit antibody (antirabbit IgG) was purchased from Rockland Immunochemicals (Gilbertsville, PA). UCN-01
was kindly supplied by was provided by the Cancer Treatment and Evaluation Program of
the National Cancer Institute. VP-16 was purchased from Sigma.
C. Methods:
Cell culture: Parental HCT116 colon cancer cells (WT cells) were cultured in DMEM
media containing 5% fetal bovine serum and 1% Penicillin/Streptomycin. Lapatinib
resistant HCT116 cells (WT-AD cells) were cultured in DMEM media containing 5% fetal
bovine serum, 1% Penicillin/Streptomycin and 2µM Lapatinib. When WT-AD cells were
thawed out of the freezer, they were plated in DMEM media containing 5% fetal bovine
serum, 1% Penicillin/Streptomycin and 10µM Lapatinib for 3 days to ensure they were
Lapatinib resistant.
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Detection of Cell Death by Trypan Blue Assay: After treatment, medium was removed
and cells were washed in 1X PBS. Cells were then harvested by trypsinization with
Trypsin/EDTA for 5 min at 37°C. Because some apoptotic cells detached from the culture
substratum into the medium, these cells were also collected by centrifugation of the
medium at 1400 RPM for 5 min. The pooled cell pellets were resuspended and mixed with
trypan blue dye. Trypan blue stain, in which blue dye-incorporating cells were scored as
being dead, was performed by counting of cells using a light microscope and a
hemacytometer. The number of dead cells was counted and expressed as a percentage of
the total number of cells counted.
Culture of Cells and Drug Treatments for Colony Formation Assays: Cells were
plated (250–1000 cells/well of a 6-well plate). 12 h after plating medium was removed and
serum-free medium was added to the cells for 24 or 48 h as indicated. After this, the serumfree media was carefully removed and fresh media (with serum) was added. Colony
formation assays were cultured for an additional 8-10 days, after which the media were
removed, cells were fixed with methanol, stained with crystal violet, and counted manually.
Immunoprecipitation and Western Blotting: 12 hours after plating cells, they were
either infected with CD533 and CD572 or control virus for 24h or serum starved and
treated with indicated concentrations of lapatinib or dimethyl sulfoxide (DMSO) for 2h.
After either of these treatments, cells were treated with 20ng/ml EGF or vehicle for 10
mins. Cells were then scraped using RIPA buffer (50mM Tris HCl pH 7.4, 150mM NaCl,
1%NP-40, 1% Sodium Deoxycholate, 1mM PMSF, 1mM Sodium orthovanadate, 10mM
Sodium Fluoride, 10mM β-glycerophosphate, 0.5mM EGTA, 0.5mM EDTA and protease
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inhibitor cocktail purchased from (Roche)) and ERBB1 or ERBB2 was
immunoprecipitated as indicated, after which samples were boiled for 10 minutes in whole
cell lysis buffer (0.5 M Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 1% β-mercaptoethanol,
0.02% bromophenol blue). 12 hours after plating cells, they were also scraped using a nondenaturing lysis buffer (50mM Tris HCl pH 7.4, 150mM NaCl, 1%NP-40, 0.1% sodium
deoxycholate, protease and phosphatase inhibitor cocktails (Roche)) and mutant p53 was
immunoprecipitated after which samples were boiled for 10 min in whole cell lysis buffer.
Cells were also scraped in CHAPS buffer (10mM HEPES, 140mM NaCl, 1% CHAPS) and
then active BAK or active BAX was immunoprecipitated. Samples were boiled for 10 min
in whole cell lysis buffer. All samples were then loaded on 8%-16% Criterion pre-cast gels
(BIORAD) after normalizing total protein and run for about 2 hours. Proteins were then
electrophoretically transferred onto 0.22um nitrocellulose membranes and immunoblotted
with various primary antibodies as indicated.
Virus Infections: Cells were infected 12h after plating with adenoviruses at an
approximate multiplicity of infection of 30 for 4 h with gentle rocking, after which time the
media was replaced. Cells were further incubated for 24 h to ensure adequate expression of
transduced gene products before drug exposures.
Transfection of Cells with Small Interfering RNA Molecules: RNA interference for
down-regulating the expression of AIF, Mcl-1, Bcl-xl and BAK was performed using
validated target sequences designed by Qiagen. For transfection, 20-40 nM concentration
of the annealed siRNA-targeting AIF, Mcl-1, Bcl-xl or BAK, or the negative control (a
"scrambled" sequence with no significant homology to any known gene sequences from
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mouse, rat, or human cell lines) were used. The siRNA molecules were transfected into
cells according to the manufacturer's instructions. Cells were cultured for 24 h after
transfection before any additional experimentation.
Cell Fractionation: 12h after plating cells, they were serum starved and treated with 2µM
lapatinib or DMSO for 36h. This experiment was performed on ice at all times. Medium
from plates was then aspirated and cells were scraped in buffer (75mM
NaCl+8mMNa2HPO4+1mMNa2H2PO4+0.5mMEDTA+ 0.5mMEGTA with freshly added
350ug/ml digitonin, 250mM sucrose, protease and phosphatase inhibitor cocktails (Roche))
and passed through a 25 gauge needle 12 times. After 15 to 30 minutes on ice, cells were
spun down at 5000RPM for 1.5 minutes at 4oC to remove cell debris. Pellet was discarded
and supernatant was transferred to a new tube and spun down at 13000 RPM for 25
minutes at 4oC. The supernatant obtained is the cytosolic fraction where as the pellet is the
mitochondrial fraction. Whole cell lysis buffer was added to the supernatant and the pellet,
boiled for 10 minutes and then western blot analysis was performed. This protocol was
adapted from Leist M, et. al. (1998).
Flow Cytometry: Flow cytometric analysis of cells was performed after staining by the
the ANNEXIN V-FITC kit (Beckman Coulter) according to the manufacturer’s
instructions and read on Beckton Dickinson FACScan.
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D. Results:
Generation of Lapatinib resistant HCT116 cells: HCT116 colon cancer cells (henceforth
called WT cells) were cultured in the presence of 10µM lapatinib, a concentration that is
below the lapatinib Cmax in patients (GlaxoSmithKline). Within 72 h of lapatinib treatment,
many cells became detached and died from this drug exposure. Cells were cultured in the
presence of 10µM lapatinib for a further ~3 months until a homogeneous population of
cells grew out from the survivors that were resistant to lapatinib (henceforth called WTAD cells).
Confirmation of Lapatinib resistance in WT-AD cells: 24 h after plating WT and WT-AD
cells, they were serum-starved and exposed to increasing concentrations of lapatinib (0-10
µM) for 48 h. Trypan blue analysis showed that at each concentration of lapatinib tested,
WT-AD cells showed significantly lower levels of cell death compared to WT cells (Figure
3). The level of cell death observed in WT-AD cells treated with 10 µM lapatinib, which
was the highest concentration of lapatinib used in this experiment, was comparable to the
level of cell death observed in WT cells that were simply serum-starved (i.e. no lapatinib
was added). Also, WT-AD cells were significantly protected from serum-starvation
induced cell death compared to WT cells. This indicates that compared to WT cells, WTAD cells are resistant to lapatinib as well as serum-starvation.
In another experiment, WT and WT-AD cells were serum-starved and exposed to vehicle
or 2µM lapatinib for varying times (12 h – 48 h) and cell viability was measured by
Annexin-PI staining flow cytometric analysis. Results confirmed that WT-AD cells were
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resistant to the effects of 2µM lapatinib as well as serum-depletion compared to WT cells
at each time point tested (Figure 4).
WT and WT-AD cells were treated with either vehicle or increasing doses of lapatinib
(0.1-10µM) without serum-starvation. Annexin-PI flow cytometric analysis showed that
WT-AD cells were more resistant to the cyto-toxic effects of lapatinib at all doses tested
compared to WT cells even in the presence of serum (Figure 5).
Reinforcing our previous observations, colony formation assays showed that WT-AD cells
are more resistant to the effects of serum-starvation than WT cells (Figure 6). Colony
formation assays also showed that ionizing radiation reduced survival by comparable
levels in both WT and WT-AD cells (Figure 7).
Culturing WT-AD cells in the absence of lapatinib: To investigate whether lapatinib
resistant WT-AD cells maintained their resistant phenotype if cultured in the absence of
lapatinib, these cells were cultured without lapatinib for >10 flask passages (~2 months)
and are labeled WT-AD10. Cell death levels in serum-starved WT-AD10 cells were not
significantly different than the levels in serum-starved WT-AD cells under vehicle as well
as lapatinib treated conditions. WT-AD and WT-AD10 cells showed much lower cell death
levels compared to WT cells under serum starved conditions in the presence of vehicle or
2µM lapatinib. Hence, WT-AD10 cells maintained their resistance to serum-starvation as
well as lapatinib in spite of being cultured in the absence of the drug (Figure 8).
Effect of chemotherapeutic agents on WT and WT-AD cells: To determine whether WTAD cells were cross-resistant to toxicity induced by commonly used chemotherapeutic
agents, WT-AD and WT cells were treated with other chemotherapeutic agents namely,
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VP-16 (etoposide), UCN-01 (an analogue of staurosporine) and Taxotere. WT-AD cells
were significantly more resistant to all of these agents than parental WT cells at all doses
tested (Figure 9 and 10).
Effect of lapatinib on ERBB1 receptor activation: Next we wanted to determine whether
lapatinib was able to inhibit ERBB1 receptor activation in WT and WT-AD cells.
Increasing concentrations of lapatinib (0-2μM) resulted in increased inhibition of basal and
epidermal growth factor (EGF) induced ERBB1 tyrosine phosphorylation in WT and WTAD cells (Figure 11). This confirmed that lapatinib was able to inhibit ERBB1 receptor
activation in both cell lines and that lack of lapatinib uptake in WT-AD cells was not the
mode of resistance in these cells. It was also noted that total ERBB1 levels in WT and WTAD cells were comparable as judged by immunoblotting of whole cell lysates.
Cell surface ERBB1 receptor level in WT and WT-AD cells: Results from the previous
experiment showed that basal and EGF stimulated levels of ERBB1 receptor tyrosine
phosphorylation in WT-AD cells appeared to be lower compared to WT cells. Also, EGF
mediated ERK1/2 phosphorylation in WT-AD cells was observed to be reduced compared
to WT cells (Figure 11). These data suggested that there may be fewer cell surface ERBB1
receptors available for activation in WT-AD cells compared to WT cells. To investigate
this possibility, immunocytochemistry was performed to look at the cell surface level of
ERBB1 receptors in non-permeabilized, serum-starved WT and WT-AD cells. Results
indicated that WT-AD cells appeared to have considerably lower plasma membrane
associated ERBB1 levels compared to WT cells which could possibly explain why basal
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and EGF induced ERBB1 phosphorylation appeared to be lower in WT-AD cells than in
WT cells (Figure 12).
VEGFR and c-KIT levels are comparable in WT and WT-AD cells: Over-expression of
other growth factor receptors such as VEGFR-1 and c-KIT has been implicated in
mediating resistance to chemotherapeutic agents (Bianco R, et. al. 2008; Raspollini MR,
et. al. 2004). Immunoblotting analysis showed that levels of VEGFR-1 and c-KIT receptor
were similar in WT and WT-AD cells and hence unlikely to be responsible for mediating
lapatinib resistance in WT-AD cells (Figure 13).
Role of Src, IGF-1R, estrogen receptor (ER), NF-κB or STAT in mediating lapatinib
resistance: Since previous studies have implicated Src and IGF-1R in mediating drug
resistance we wanted to investigate whether these kinases were important in mediating
lapatinib resistance in WT-AD cells (Qin B, et. al. 2006; Lu Y, et. al. 2001). Inhibition of
neither Src family kinases using the inhibitor PP2 nor IGF-1R function using the inhibitor
PPP restored lapatinib sensitivity in WT-AD cells (Figure 14). It is noteworthy that
inhibition of the IGF-1R with PPP caused significant toxicity in parental WT cells that was
abolished in WT-AD cells. These data suggested that Src and IGF-1R were not primary
mediators on lapatinib resistance in WT-AD cells.
Previous studies have also implicated ER, NF-κB and STAT proteins in mediating drug
resistance in cancer cells (Xia W, et. al. 2006; Herrmann JL, et. al. 1997; Sumitomo M, et.
al. 1999; Catlett-Falcone R, et. al. 1999). Hence, we wanted to determine whether any of
these proteins played a role in mediating lapatinib resistance in WT-AD cells. Incubation
of WT-AD cells with ER inhibitor 4-hydroxy tamoxifen in phenol-red free media,
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inhibition of NF-κB function by over-expression of IκB super-repressor (dominant
negative IκB) or inhibition of STAT function by expression of STAT inhibitory peptide
did not restore lapatinib sensitivity in WT-AD cells (Figure 15). In control studies, it was
noted that expression of super-repressor IκB or STAT inhibitory peptide suppressed
reporter construct activity in WT and WT-AD cells and in phenol red-free media, basal
estrogen receptor activity was reduced by tamoxifen treatment in both WT and WT-AD
cells (Figure 16). These control studies confirmed that super-repressor IκB, STAT
inhibitory peptide and 4-hydroxy tamoxifen were functional.
Role of multi-drug resistance (MDR) pumps in mediating lapatinib resistance: Since
studies have shown that MDR pumps can mediate drug resistance in cancer cells,
immunoblotting was performed to determine whether MDR pumps had a role to play in
mediating lapatinib resistance in WT-AD cells (Szakacs G, et. al. 2006). Little change was
observed in the levels of MRP-1, ABCG-2 and Pgp transporters in WT and WT-AD cells
suggesting that these MDR pumps were not major players in mediating lapatinib resistance
in WT-AD cells (Figure 17).
Levels of pro- and anti-apoptotic proteins in WT and WT-AD cells: Alterations in the
levels of Bcl-2 family members have been shown to mediate drug resistance in cancer cells
(Raffo AJ, et. al. 1995; Tsujimoto Y, et. al. 1984; Fulda S and Debatin KM. 2006;
Meijerink JP, et. al. 1998). To investigate this possibility in WT-AD cells, immunoblotting
studies were performed which indicated that compared to WT cells, WT-AD cells
expressed higher levels of p53 as well as anti-apoptotic Bcl-2 family proteins namely, Mcl1 and Bcl-xl (Figure 18). Over-expression of Bcl-xl abolished lapatinib toxicity on WT
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cells (Figure 19). WT-AD cells expressed lower levels of pro-apoptotic protein BAX
compared to WT cells (Figure 18). Further, immunoprecipitation studies showed that upon
treatment with lapatinib, WT-AD cells have reduced BAK and BAX activation compared
to WT cells (Figure 18). This occurred in spite of the observation that total BAK levels
appeared to increase in WT-AD cells, post lapatinib treatment.
In WT-AD cells, knockdown of Mcl-1 expression, to a greater extent than that of Bcl-xl,
partially reverted lapatinib resistance by ~50% compared to WT cells treated with lapatinib
(Figure 20). In WT-AD cells, knockdown of BAK activation significantly reduced the
reversion of their resistant phenotype due to Mcl-1 knock-down (Figure 21).
Role of p53 in lapatinib resistance: Previous immunoblotting data indicated that WT-AD
cells showed less p53 phosphorylation under vehicle or lapatinib treated conditions
compared to WT cells. This is important since phosphorylation has been shown to play an
important role in stabilizing and activating p53 so that it can elicit an appropriate response
to cellular stress (Jimenez GS, et. al. 1999). Also, WT-AD cells have higher total p53
levels than WT cells. It is known that in cancer cells, p53 expression is often elevated
when p53 is mutated (Kohler MF, et al. 1992). Hence, we wanted to further investigate
whether p53 in WT-AD cells was mutated. Native p53 proteins were immunoprecipitated
from WT and WT-AD cells using an antibody that specifically recognizes mutant forms of
p53, as judged by the recognition of mutant p53 tertiary structure within the DNA binding
domain of p53. The p53 proteins were then separated on denaturing SDS-PAGE and
immunoblotted. WT-AD cells, but not WT cells, immunoprecipitated “mutant” p53
(Figure 22). Total mRNA was isolated from WT and WT-AD cells, amplified and
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sequenced using primers specific for the DNA binding domain of p53. We noted, however,
that a mutation in the p53 DNA binding domain was not detected in WT-AD cells. Further
experiments will be required to investigate the role of p53 in WT-AD cells.
Co-expression of dominant negative ERBB1 and ERBB2 to mimic lapatinib treatment:
In order to investigate the mechanism of lapatinib mediated cell death, dominant negative
ERBB1 and ERBB2 receptors were expressed in WT and WT-AD cells. Co-expression of
dominant negative ERBB1 (CD533) and dominant negative ERBB2 (CD572) proteins
inhibited both basal and EGF mediated ERBB1 and ERBB2 tyrosine phosphorylation in
WT cells (Figure 23A). In spite of inhibiting ERBB1 and ERBB2 tyrosine phosphorylation
similar to lapatinib, trypan blue analysis showed that co-expression of CD533 and CD572
failed to recapitulate the toxic effects of lapatinib in serum-starved WT and WT-AD cells
suggesting that lapatinib mediated cell death may involve mechanisms in addition to/other
than inhibition of the ERBB receptor system (Figure 23C). Also, in WT cells, the lack of
increased cell death in the presence of CD533 and CD572 was not due to the inability of
these dominant negative receptors to inhibit survival pathways downstream of ERBB
receptors as shown by their capability to inhibit ERK1/2 and AKT phosphorylation (Figure
23B).
Role of caspases in lapatinib mediated cell death: In WT cells, it was noted that inhibition
of caspase enzymes resulted in protection from cell death induced by serum starvation
(Figure 24). However, inhibition of caspase 8 or caspase 9 or treatment with a pan-caspase
inhibitor did not protect WT cells from lapatinib mediated cell death (Figure 25). This
indicated that lapatinib mediated cell death was likely caspase independent. As calpains,
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cathepsins and serine proteases can also initiate cell death pathways, we wanted to
investigate whether they were involved in lapatinib mediated cell death (Vandenabeele P,
et. al. 2005; Droga-Mazovec G, et. al. 2008; Broker LE, et. al. 2004). Inhibition of
calpains, cathepsins and serine proteases did not protect WT cells from lapatinib toxicity
suggesting that they were not likely involved in lapatinib mediated cell death (Figure 26
and 27).
Caspase independent mechanism of lapatinib mediated cell death: Since previous
experiments suggested that lapatinib mediated cell death was likely caspase independent,
we wanted to investigate the role of apoptosis inducing factor (AIF) as it is thought to
initiate cell death pathways independent of caspase enzymes (Penninger JM and Kroemer
G. 2003). Immunoblotting and cell fractionation studies showed that increased cytosolic
release of AIF as well as cytochrome c was observed in WT cells treated with lapatinib but
not in WT-AD cells under the same conditions (Figure 28). Knockdown of AIF expression
reduced lapatinib toxicity in WT cells, and knockdown of AIF expression combined with
pan-caspase inhibition further reduced lapatinib toxicity in these cells (Figure 29).
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Figure 3: WT-AD cells are resistant to effects of lapatinib and serum-starvation.
Parental HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WT-AD) were plated
and 24 h after plating were grown in serum-depleted medium in the presence or absence of
vehicle (DMSO) or lapatinib (0–10µM). Cells were isolated 48 h after
serum-starvation/lapatinib addition, and cell viability was determined by trypan blue
exclusion assay. Significant effects of lapatinib dose and cell type were observed (Twoway ANOVA p < 0.0001, n=6). Bonferroni’s post-test revealed that under vehicle treated
conditions and at each concentration of lapatinib tested, there was significantly higher cell
death in WT cells compared to WT-AD cells (p < 0.0001). Data (mean ± S.E.M.) are from
two independent experiments combined.
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Figure 4: WT-AD cells are resistant to effects of lapatinib.
Parental HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WT-AD) were plated
and 24 h after plating were grown in serum-depleted medium in the presence or absence of
vehicle (DMSO) or 2µM lapatinib. Cells were isolated at the indicated times, and cell
viability (indicated under each panel) was determined by annexin-PI flow cytometric
analysis (n=6). Data (mean ± S.E.M.) are from two independent experiments combined.
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Figure 5: WT-AD cells are resistant to effects of lapatinib
24 h after plating parental HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WTAD), they were treated with vehicle (DMSO) or increasing concentrations of lapatinib(0.110μM). 48 h later, cells were isolated and cell viability (indicated under each panel) was
determined by annexin-PI flow cytometric analysis (n=6). Data (mean ± S.E.M.) are from
two independent experiments combined.
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Figure 6: WT-AD cells are resistant to serum-starvation.
Parental HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WT-AD) were plated
as single cells and 12 h after plating were placed into serum-depleted medium for either 24
or 48. Colonies were permitted to form over the following 10 to 14 days in fresh media
with serum and no lapatinib, after which the media were removed, the colonies fixed and
stained with crystal violet, and the colonies of >50 cells were counted. Significant effect of
serum starvation duration was observed in both cell lines (p < 0.0001, Two-way ANOVA,
n=8) and Bonferroni’s post test revealed that 48 h after serum starvation, WT cells showed
significantly decreased survival than WT-AD cells (p < 0.05). Data (mean ± S.E.M.) are
from two independent experiments combined.
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Figure 7: Ionizing radiation affects WT and WT-AD cell survival.
Parental HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WT-AD) were plated
as single cells in sextuplicate and 12 h after plating were exposed to ionizing radiation (03Gy). Colonies were permitted to form over the following 10 to 14 days, after which the
media were removed, the colonies fixed and stained with crystal violet, and the colonies of
>50 cells were counted. A significant effect of radiation dose in both cell lines (p < 0.0001,
Two-way ANOVA, n=8) but no significant difference in the cell types was observed. Data
(mean ± S.E.M.) are from two independent experiments combined.
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Figure 8: Absence of lapatinib in culture does not restore lapatinib sensitivity in WTAD cells. Parental HCT116 cells (WT), HCT116 lapatinib-resistant cell (WT-AD) and
HCT116 lapatinib-resistant cells that had been grown for ~2 months in the absence of
lapatinib (WT-AD10) were plated and 24 h after plating were grown in serum-depleted
medium in the presence or absence of vehicle (DMSO) or lapatinib (2µM). Cells were
isolated 48 h after serum starvation/lapatinib addition, and cell viability was determined in
triplicate by trypan blue exclusion assay. Student’s t-test showed that there was no
significant difference between cell death levels in WT-AD and WT-AD10 cells under
vehicle or lapatinib treated conditions. Data (mean ± S.E.M.) are from two independent
experiments combined.

48
30

36 h

20

15

10

WT-AD
3 uM

WT

WT-AD

2 uM

1 uM

WT

WT-AD

WT

WT
0.3 uM

Vehicle

WT

0

WT-AD

5

WT-AD

Percentage cell death

25

VP-16
100

60

40

WT-AD
3uM

WT

WT-AD
1uM

WT

WT-AD
0.6uM

WT

WT-AD
0.3uM

WT

WT

WT-AD
0.1uM

Vehicle

0

WT-AD

20

WT

Percentage cell death

36 h
80

UCN-01

Figure 9: WT-AD cells are resistant to effects of VP-16 and UCN-01.
Parental HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WT-AD) were treated
with increasing concentrations of VP-16 (0-3μM) or UCN-01 (0-3μM). 36 h later, cell
viability was determined by trypan blue exclusion assay. For both experiments effects of
dose and cell type were observed (Individual Two-way ANOVA, p < 0.0001, n=6).
Bonferroni’s post test revealed higher levels of cell death in WT cells relative to WT-AD
cells under vehicle conditions and with VP-16 and UCN-01 treatment at all concentrations
tested.
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Figure 10: WT-AD cells are resistant to effects of Taxotere.
Parental HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WT-AD) were treated
with increasing concentrations of Taxotere (0-300nM). 48 h later, cell viability was
determined by trypan blue exclusion assay. An effect of dose and an effect of cell type
were observed (Two-way ANOVA, p < 0.0001, n=6). Bonferroni’s post test revealed that
with increasing concentration of Taxotere, significantly higher level of cell death was
observed in WT cells compared to WT-AD cells under each condition. Data (mean ±
S.E.M.) are from two independent experiments combined.
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Figure 11: Lapatinib inhibits ERBB1 and ERBB2 phosphorylation in WT and WTAD cells. Parental HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WT-AD)
were plated and 24 h after plating were grown in serum-depleted medium for 2 h followed
by treatment with vehicle (DMSO) or lapatinib (L, 0–2 μM), as indicated. Thirty minutes
after lapatinib exposure, cells were treated as indicated with 20 ng/ml EGF. Ten minutes
after EGF addition, cells were harvested and subjected to lysis, and portions of the lysate
either were immunoprecipitated to isolate ERBB1 and determine ERBB1 tyrosine
phosphorylation or were directly subjected to SDS-PAGE to determine total ERBB1,
GAPDH and ERK2 expressions and ERK1/2 phosphorylation. A representative study is
shown (n = 2).
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Figure 12: WT-AD cells appear to have fewer cell surface ERBB1 receptors than WT
cells. Parental HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WT-AD) were
plated and 24 h after plating were grown in serum-depleted medium for 2 h. Cells were
fixed but not permeabilized, and cell surface levels of ERBB1 were determined by
immunostaining and examination under fluorescent light microscope. Two representative
images from one experiment are shown. Quantitative assessment of increase in
fluorescence intensity was determined from fifty cells counted over two independent
experiments.
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Figure 13: No change in VEGFR and c-KIT receptor levels in WT-AD cells.
Parental HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WT-AD)
were plated and 24 h later were lysed and lysate was subjected to SDS PAGE followed by
immunoblotting to determine the expression of c-KIT and VEGFR-1 receptors as well as
ERK2 as a loading control.
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Figure 14: Lapatinib resistance in WT-AD cells is unlikely to be mediated via Src or
IGF-1R. Parental HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WT-AD)
were plated and 24 h later were grown in serum-depleted medium with vehicle (DMSO),
Lapatinib (2μM), PP2 (10μM), PPP (250nM), or the drug combinations indicated. Cells
were isolated 48 h after serum starvation, and cell viability was determined trypan blue
exclusion assay. Data (mean ± S.E.M.) are from two independent experiments combined.
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Figure 15: Lapatinib resistance in WT-AD cells is unlikely to be mediated via
estrogen receptor, NFκB or STAT. A) Parental HCT116 cells (WT) and HCT116
lapatinib-resistant cells (WT-AD) were plated and 24 h after plating were grown in serumdepleted, phenol red-free medium in the presence or absence of vehicle (DMSO), 4hydroxytamoxifen (4-OH TAM, 50 nM) or lapatinib (2μM); B) HCT116 lapatinib resistant
cells (WT-AD) were plated and 12 h after plating were infected with either a control empty
vector adenovirus or a recombinant adenovirus to express dominant-negative IκB (dnIκB).
24 h after virus infection, cells were grown in serum-depleted medium in the presence or
absence of vehicle (DMSO) or lapatinib (0–3μM). Cells were isolated 48 h after drug
addition, and cell viability was determined by trypan blue exclusion assay; C) HCT116
lapatinib-resistant cells (WT-AD) were plated and 12 h after plating were infected with
either a control empty vector adenovirus or a recombinant adenovirus to express dominant
negative STAT3 (dnSTAT3). 24 h after virus infection, cells were grown in serumdepleted medium in the presence or absence of vehicle (DMSO) or lapatinib (3μM). Cells
were isolated 48 h after drug addition, and cell viability was determined by trypan blue
exclusion assay. Data (mean ± S.E.M.) are from two independent experiments combined.
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Figure 16: Tamoxifen, STAT IP and dn IκB inhibit reporter construct activity in WT
and WT-AD cells. 24 h after plating HCT116 cells (WT) and HCT116 lapatinib-resistant
cells (WT-AD) in triplicate, they were infected with vector control virus (CMV), a virus to
express dominant negative IκB (dnIκB), or treated with STAT3 inhibitory peptide (STAT
IP). 24h later, cells were transfected with plasmids to express firefly luciferase under
NFκB or STAT promoter regulation, respectively, together with an internal control renilla
luciferase plasmid under constitutive expression. Parallel triplicate sets of plates of WT
and WT-AD cells in phenol red free media were plated and 24 h later were transfected to
express firefly luciferase under an estrogen responsive element (ERE), together with an
internal control renilla luciferase plasmid under constitutive expression. 24 h later, cells
were treated with Vehicle (VEH, DMSO) or 4-Hydroxy-tamoxifen (TAM, 50nM).
Promoter activity for ERE, STAT and NFκB elements was measured 24 h aftr
transfection/tamoxifen addition and corrected for transfection efficiency using the renilla
luciferase plansmid ±S.E.M. (n=3). *, p < 0.05 less than corresponding vehicle
control/vector control value (Student’s t-test).
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Figure 17: Lapatinib resistance in WT-AD cells is unlikely to be mediated via MDR
pumps. 24 h after plating HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WTAD), they were serum-starved for 24 h. Cells were then isolated and cell lysates were
subjected to SDS PAGE followed by immunoblotting to determine the expression of
MRP1, Pgp and ABCG2. Loading controls (GAPDH and EF1) were also measured. As a
positive control for Pgp, lysates from doxorubicin resistant SW480 cells was included.
Data from representative study (n=2).
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Figure 18: Alterations in protein levels in WT-AD cells. Parental HCT116 cells (WT)
and HCT116 lapatinib-resistant cells (WT-AD) were plated and 24 h later were grown in
serum-depleted medium in the presence or absence of vehicle (DMSO) or lapatinib (2μM).
Cells were isolated 48 h after lapatinib addition and were subjected to SDS-PAGE to
determine the expression of multiple proteins. Or, cell were isolated 36 h after serum
depletion/lapatinib addition, cells were isolated for immunoprecipitation to determine the
amount of the activated forms of BAX and BAK. Representative images shown (n=2).
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Figure 19: Bcl-xl over-expression protects WT cells from effects of lapatinib. Parental
HCT116 cells (WT) were plated and 12 h after plating were infected with either a control
empty vector adenovirus or a recombinant adenovirus to express BCL-XL. 24 h after virus
infection, cells were grown in serum depleted medium in the presence or absence of
vehicle (DMSO) or lapatinib (2μM). Cells were isolated 48 h after drug addition, and cell
viability was determined by trypan blue exclusion assay. One-way ANOVA (n=6) revealed
that lapatinib induced significantly high cell death compared to all other conditions (p <
0.0001) and over-expression of BCL-xl significantly protected WT cells from cell death
under both basal (p < 0.05) and laptinib treated conditions (p < 0.0001). Data (mean ±
S.E.M.) are from two independent experiments combined.

Percentage cell death

59

Figure 20: Knockdown of Mcl-1 partially reverted lapatinib resistance in WT-AD
cells. Parental HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WT-AD) were
plated and 12 h later as indicated were transfected with siRNA molecules to reduce the
expression of nothing/control (siSCR), Bcl-xl (siBcl-xl), or Mcl-1 (siMcl-1). 48 h after
transfection, cells were grown in serum-depleted medium in the presence or absence of
vehicle (DMSO) or Lapatinib (2μM) as indicated. Cells were isolated 36 h after serum
starvation, and cell viability was determined by trypan blue exclusion assay. $, p < 0.05
greater than corresponding HCT116 siSCR + lapatinib cell value (Student’s t-test, n=2).
Data (mean ± S.E.M.) are from two independent experiments combined.
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Figure 21: In WT-AD cells, knockdown of BAK reduced reversion of resistant
phenotype due to Mcl-1 knock-down. HCT116 lapatinib-resistant cells (WT-AD) were
plated and 12 h later as indicated were transfected with siRNA molecules to reduce the
expression of nothing/control (siSCR), MCL-1 (siMCL-1), BAK (siBAK), or MCL-1 and
BAK (siMCL+siBAK). Forty-eight hours after transfection, cells were grown in serumdepleted medium in the presence or absence of vehicle (DMSO) or lapatinib (2 µM). Cells
were isolated 48 h after serum starvation, and cell viability was determined by trypan blue
exclusion assay. One-way ANOVA (n=6) with Bonferroni’s post test revealed that
lapatinib induced significantly higher level of cell death compared to vehicle treated cells,
knock-down of MCL-1 further significantly enhanced lapatinib lethality compared to all
other conditions, knock-down of BAK significantly reduced lapatinib mediated cell death
(p < 0.001) and knock-down of BAK and MCL-1 simultaneously not only prevented
lapatinib mediated cell death (p < 0.001) but also reverted MCL-1 mediated enhancement
of lapatinib induced cell death (p < 0.001). Data (mean ± S.E.M.) are from two
independent experiments combined.
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Figure 22: “Mutant” p-53 immunoprecipitated in WT-AD cells. Parental HCT116 cells
(WT) and HCT116 lapatinib-resistant cells (WT-AD) were plated and 24 h after plating
were lysed and prepared for immunoprecipitation and pseudoimmunoprecipitation with or
without mixing with agarose beads against mutated inactive p53 followed by SDSPAGE.
The mixing with or without agarose beads was to ensure as a control that no spurious
effects were observed on the SDS-PAGE mobility of p53 due to agarose bead inclusion in
the loading of the gel. The SDS-PAGE was transferred to nitrocellulose and probed with
an anti-p53 antibody and an anti-GAPDH antibody. Two representative images shown
from three separate studies.
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Figure 23: Dominant negative ERBB1 and ERBB2 fail to produce lapatinib like cell
death levels in WT cells. A) Parental HCT116 cells (WT) were plated and 12 h after
plating were infected with either a control empty vector adenovirus (CMV) or recombinant
adenoviruses to express dominant-negative ERBB1-CD533 and dominant negative
ERBB2-CD572. 24 h later, cells were grown in serum-depleted medium for 2 h and then
treated with 20 ng/ml EGF as indicated for 10 min. Cells were isolated and subjected to
immunoprecipitation of ERBB1 or ERBB2 followed by SDS-PAGE as indicated followed
by anti-phospho-tyrosine blotting to determine the activation of ERBB1/2 proteins. A
representative study is shown (n = 3). B) CD533 and CD572 also inhibit basal ERK and
AKT phosphorylation. A representative study is shown (n = 2). C) 12 h after plating WT
and WT-AD cells, they were infected with CMV, CD533, CD572 or both CD533 and
CD572. 24h later, cells were grown in serum-depleted medium. Cells were isolated 48 h
after serum starvation, and cell viability was determined by trypan blue exclusion assay.
No significant effect on cell death was observed in either cell line under each condition
tested (One-way ANOVA). Data (mean ± S.E.M.) are from two independent experiments
combined.
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Figure 24: Inhibition of caspases protects WT cells from serum starvation induced
death. Parental HCT116 cells (WT) were plated and 24 h later were grown in serumdepleted medium. Cells were isolated 48 h after serum-starvation and cell viability was
measured by trypan blue exclusion assay. Cells were significantly protected from the
effects of serum starvation in the presence of IETD (caspase 8 inhibitor), LEHD (caspase 9
inhibitor) and ZVAD (pan-caspase inhibitor) (p < 0.0001, One-way ANOVA, n=6). Data
(mean ± S.E.M.) are from two independent experiments combined.
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Figure 25: Inhibition of caspases fails to protect WT cells from effects of lapatinib.
Parental HCT116 cells (WT) were plated and 24 h later were grown in serum-depleted
medium in the presence or absence of vehicle (DMSO) or lapatinib (2μM). In parallel,
cells were grown in the presence or absence of vehicle (DMSO), the caspase 8 inhibitor
IETD (50μM), the caspase 9 inhibitor LEHD (50μM) or the pan-caspase inhibitor zVAD
(50μM). Cells were isolated 36 h after serum starvation, and cell viability was determined
in triplicate by trypan blue exclusion assay. One-way ANOVA with Bonferroni’s post test
revealed that WT cells were not protected from lapatinib induced cell death under any
condition (p > 0.05, n=6). Data (mean ± S.E.M.) are from two independent experiments
combined.
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Figure 26: Inhibition of calpains and/or cathepsins fails to protect WT cells from
effects of lapatinib. HCT116 cells (WT) were plated and treated with vehicle or lapatinib
in combination with Cathepsin B and/or Calpain inhibitors. 24 or 36 h after treatment, cell
viability was measured using trypan blue exclusion assay (n=6). Data (mean ± S.E.M.) are
from two independent experiments combined.
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Figure 27: Inhibition of serine proteases fails to protect WT cells from effects of
lapatinib. HCT116 cells (WT) were plated and treated with vehicle or lapatinib in
combination with serine protease inhibitor, AEBSF. 48 h after treatment, cell viability was
measured using trypan blue exclusion assay (n=6). Data (mean ± S.E.M.) are from two
independent experiments combined.
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Figure 28: Cytosolic AIF and cytochrome c release observed in WT cells treated with
lapatinib. Parental HCT116 cells (WT) and HCT116 lapatinib-resistant cells (WT-AD)
were plated and 24 h after plating were grown in serum-depleted medium in the presence
or absence of vehicle (DMSO) or lapatinib (2μM). 36 h after serum depletion/lapatinib
addition, cells were isolated for cell fractionation assay to determine AIF and cytochrome c
release into the cytosol. A representative from two separate studies is shown.
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Figure 29: Knock-down of AIF expression in WT cells reduces lapatinib toxicity.
Parental HCT116 cells (WT) were plated and 12 h later as indicated were transfected with
siRNA molecules to reduce the expression of nothing/control (siSCR) or AIF (siAIF). 48 h
after transfection, cells were grown in serum-depleted medium in the presence or absence
of vehicle (DMSO), lapatinib (2μM), in parallel with or without pan-caspase inhibitor
zVAD (50μM), as indicated. Cells were isolated 36 h after serum starvation, and cell
viability was determined by trypan blue exclusion assay. *, p < 0.05 less than
corresponding siSCR cell value; #, p < 0.05 less than parallel siSCR value (Student’s t-test,
n=6). Data (mean ± S.E.M.) are from two independent experiments combined.
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E. Discussion:
Development of resistance to chemotherapeutic agents is a common occurrence in the
clinic (Kobayashi S, et. al. 2005). This study investigated the mode of lapatinib action as
well as the mechanism of lapatinib resistance in HCT 116 colon cancer cells. We have
shown that resistance to lapatinib is possible in colon cancer cells using cell viability as
well as cell survival assays. These studies show that lapatinib resistant HCT 116 (WT-AD)
cells are indeed resistant to lapatinib and also to serum-starvation (Figure 3, 4, 5, 6). It is
known that refractory cancers are difficult to manage since often times they are not only
resistant to the primary drug that was used to treat the cancer but also to other
chemotherapeutic agents (Kobayashi S, et. al. 2005). To investigate whether this was true
in the case of WT-AD cells, we treated WT (parental HCT116 cells) and WT-AD cells
with various chemotherapeutic agents. Results showed that as expected, WT-AD cells
were significantly more resistant to other chemotherapeutic agents that we tested, namely,
UCN-01, VP-16 and Taxotere compared to WT cells (Figure 9,10). Another important
finding was that the presence of lapatinib in the culture medium of WT-AD cells was not
essential to maintain their lapatinib resistant phenotype (Figure 7). This shows that
removal of lapatinib from the culture media of WT-AD cells does not restore lapatinib
sensitivity in these cells.
Studies have shown that one of the mechanisms by which cells can become resistant to
ERBB tyrosine kinase inhibitors is by outgrowth of cells that have a mutation in the
tyrosine kinase domain such that the inhibitor can no longer bind to the receptor (Pao W,
et. al. 2005; Sok JC, et. al. 2006). Our studies show that lapatinib is able to inhibit basal
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and EGF stimulated levels of ERBB1 receptor phosphorylation in both WT and WT-AD
cells (Figure 11). This suggests that it is unlikely that a mutation in the ERBB1 receptor,
such that it can no longer bind lapatinib, is the mechanism of lapatinib resistance in WTAD cells. These results also indicate that lapatinib intake is not disrupted in WT-AD cells
and hence is not a mode of lapatinib resistance in these cells. It was noted that in spite of
total ERBB1 levels in the two cell types being similar, both basal and EGF stimulated
levels of ERBB1 receptor phosphorylation in WT-AD cells appeared to be lower compared
to WT cells (Figure 11). To investigate the reason behind this observation,
immunocytochemistry studies were performed to look at cell surface levels of ERBB1
receptors available for activation in non-permeabilized WT and WT-AD cells under
serum-starved conditions. Results showed that WT-AD cells appeared to have a lower cell
surface ERBB1 receptor level than WT cells (Figure 12). Hence, this can also explain why
EGF treatment resulted in a lower level of ERK1/2 phosphorylation in WT-AD cells
compared to WT cells.
Studies have shown that resistance to ERBB receptor inhibitors can occur due to overexpression of other receptors and tyrosine kinases that can also mediate pro-survival
signals (Lu Y, et. al. 2001; Camirand A; Qin B, et. al. 2006; Xia W, et. al. 2006). Vascular
endothelial growth factor receptors (VEGFR) are known to play a major role in regulating
cell cycle in certain cells and VEGFR-1 has been found to be over-expressed in certain
cancer cells (Huang Y, et. al. 2007; Bianco R, et. al. 2008). c-KIT receptors are also
known to play a role in cell survival, proliferation and differentiation pathways and
increased expression of this receptor in certain cancers has been linked to poor patient
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prognosis (Taniguchi M, et. al. 1999; Mcintyre A, et. al. 2005). To determine whether
over-expression of VEGFR-1 or c-KIT receptors accounted for resistance to lapatinib in
WT-AD cells, receptor expression levels were measured in WT and WT-AD cells. Results
showed that there was no obvious difference in the expression levels of VEGFR-1 or cKIT receptors between WT and WT-AD cells (Figure 13). This suggested that lapatinib
resistance was not likely due to altered expression of these receptors.
In some cell types, including colon cancer cells, Src family nonreceptor tyrosine kinases
and the insulin-like growth factor-1 receptor tyrosine kinase (IGF-1R) have been linked to
drug resistance (Lu Y, et. al. 2001; Camirand A, et. al. 2002; Xia W, et. al. 2006). Hence,
we wanted to investigate whether these proteins had a role to play in mediating lapatinib
resistance in WT-AD cells. However, we noted that inhibition of neither Src family kinases
(using the inhibitor PP2) nor IGF-1 receptor function (using the inhibitor PPP) restored
lapatinib sensitivity in WT-AD cells (Figure 14). It is noteworthy that inhibition of the
IGF-1 receptor using PPP caused significant toxicity in WT cells but not in WT-AD cells,
arguing that WT-AD cells are also cross-resistant to agents that inhibit the function of
other receptor tyrosine kinases that are known to compensate for ERBB survival signaling.
As mentioned previously, constitutive activation of a variety of transcription factors such
as nuclear factor κB (NFκB) and signal transducers and activators of transcription (STAT)
have been implicated in mediating drug resistance (Herrmann JL, et. al. 1997; Sumitomo
M, et. al. 1999; Bewry NN, et. al. 2008). In order to investigate whether NFκB was
invovled in mediating lapatinib resistance, WT and WT-AD cells were infected with
adenovirus that over-expressed IκB super-repressor. NFκB is usually sequestered in the
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cytosol by inhibitor of κB (IκB) (Baldwin AS. 2001). IκB kinase (IKK) phosphorylates
IκB which leads to its degradation, releasing NFκB to perform its functions (Baldwin AS.
2001). However, the super-repressor IκB (S32A) lacks one of the residues that is required
to be phosphorylated by IKK to allow IκB to release NFκB. In the presence of superrepressor IκB (S32A), NFκB activation is constitutively inhibited. Hence, if lapatinib
resistance in WT-AD cells was due to constitutive NFκB activation, infection of these cells
with super-repressor IκB would inhibit NFκB activation and therefore render WT-AD cells
lapatinib sensitive. However, WT-AD cells maintained lapatinib resistance in spite of
constitutive NFκB inhibition (Figure 15B). This indicated that NFκB was not likely
invovled in mediating lapatinib resistance in WT-AD cells. To investigate the invovlement
of STAT proteins, STAT inhibitory peptide was introduced in WT-AD cells. STAT
inhibitory peptide is known to significantly lower the DNA-binding activity of STAT
proteins by forming an inactive STAT:peptide complex and reduce the levels of active
STAT:STAT dimers that can bind to promoter elements and induce transcription of genes
involved in migration, survival and proliferation (EMD Biosciences). It was noted that
treatment of WT-AD cells with STAT inhibitory peptide did not make them sensitive to
the effects of lapatinib suggesting that STAT proteins were not primary candidates
involved in mediating lapatinib resistance in WT-AD cells (Figure 15C).
Previous studies have shown that the estrogen receptor can mediate lapatinib resistance in
BT474 breast cancer cells (Xia W, et. al. 2006). Some colon cancer cells have been known
to express estrogen receptor (Cho NL, et. al. 2007; Xia W, et. al. 2006). Tamoxifen is a
selective estrogen receptor modulator (SERM) and is thought to antagonize the estrogen
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receptor in most tissues (Riggs BL and Hartmann LC. 2003). Hence, to investigate whether
estrogen receptor was involved in mediating lapatinib resistance in WT-AD cells, these
cells were treated with 4-hydroxy tamoxifen (one of the active metabolites of tamoxifen) in
phenol-red free media since phenol-red is a weak estrogen mimic and its presence may
alter the effect of 4-hydroxy tamoxifen in WT-AD cells (Reddel RR, et. al. 1983; Berthois
Y, et. al. 1986). Results showed that inhibition of estrogen receptor did not revert lapatinib
resistance in WT-AD cells indicating that unlike in BT474 breast cancer cells, estrogen
receptor did not appear to be invovled in mediating lapatinib resistance in WT-AD cells
(Figure 15A) (Xia W, et. al. 2006). In control studies, we noted that expression of superrepressor IκB, treatment with STAT inhibitory peptide or 4-hydroxy tamoxifen suppressed
reporter construct activity in parental and lapatinib resistant cells confirming that these
agents were functional (Figure 16).
Multi drug resistance pumps (MDR pumps) have been implicated in mediating drug
resistance in a variety of cancer cells as they can pump toxic drugs out of cells (Szakacs G,
et. al. 2006). In WT-AD cells, drug efflux could be a mechanism of lapatinib resistance,
particularly as we observed cross-resistance to multiple cytotoxic therapeutic drugs. Hence,
we performed immunoblotting analyses to determine the expression of multidrug-resistant
plasma membrane drug transporters that have been commonly implicated in mediating
drug resistance in cancer cells. Comparing WT and WT-AD cells, no obvious change in
the protein level of membrane drug transporters tested was observed arguing that changes
in drug efflux was unlikely to be a major component of the lapatinib-resistance mechanism
in WT-AD cells (Figure 17).
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Since we were unable to identify candidates responsible for mediating lapatinib resistance
in WT-AD cells, we decided to look at other molecules known to modulate cell death
pathways. Immunoblotting analyses showed that compared to WT cells, WT-AD cells
expressed higher levels of Mcl-1, Bcl-xl, p53 proteins and lower levels of pro-apopotic
protein BAX (Figure 18). Unlike WT-AD cells, lapatinib treatment in WT cells induced
BAK and BAX activation (Figure 18). It was noted that total BAK levels increased in
lapatinib treated WT-AD cells but no obvious increase in BAK activation was noticed
under the same conditions (Figure 18). This may occur because the increased levels of proapoptotic proteins Bcl-xl and Mcl-1 may be able to sequester any up-regulated BAK and
prevent it from being activated thereby inhibiting activation of cell death pathways. Hence,
these alterations in the Bcl-2 family proteins in WT-AD cells are likely to profoundly
protect these cells from toxic insults. Along the same lines, it was also noted that overexpression of anti-apoptotic protein Bcl-xl protected WT cells from the toxic effects of
lapatinib (Figure 19). Based on the established concept of the so-called “apoptotic
rheostat,” in which the anti-apoptotic Bcl-2 family proteins act in a dynamic balance to
suppress the pro-apoptotic signals generated by proteins such as BAX and BAK, our data
suggest that WT-AD cells could be resistant to lapatinib compared to WT cells because
they have increased expression of the mitochondrial protective proteins Bcl-xl and Mcl-1,
reduced expression of the mitochondrial toxic protein BAX and reduced activation of proapoptotic proteins BAK and BAX upon lapatinib treatment.
Since WT-AD cells had increased expression of anti-apoptotic Bcl-xl and Mcl-1 proteins,
we wanted to investigate whether knock-down of expression of one or both of these
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proteins would render WT-AD cells sensitive to lapatinib. Results showed that knockdown of Mcl-1 expression partially reverted lapatinib resistance in WT-AD cells to a
greater extent than by knock-down of Bcl-xl expression (Figure 20). Recent studies have
shown that over-expression of Mcl-1, but not Bcl-2 or Bcl-xl, abrogated BAK activation
after exposure to ABT-737 (a Bcl-2/Bcl-xl inhibitor) and roscovitine (a cyclin-dependent
kinase inhibitor), arguing that Mcl-1 plays a major role in regulating BAK function (Chen
S, et. al. 2007). This is consistent with data demonstrating that Mcl-1 binds with greater
affinity to BAK compared with Bcl-xl (IC50 < 10 versus < 100 nM) (Willis SN, et al.
2005). In WT-AD cells, knock-down of BAK activation significantly reduced the reversion
of their resistant phenotype by reduced Mcl-1 expression (Figure 21). Thus, the
mechanism of lapatinib resistance in WT-AD cells seems to be in part due to the loss of
BAX expression and loss of BAK activation primarily due to over-expression of Mcl-1.
Along these lines, a recently published study showed that in human H3255 non-small-cell
lung cancer cells, Erlotinib (a tyrosine kinase inhibitor of ERBB1) induced mitochondriamediated apoptosis via loss of mitochondrial membrane potential, cytosolic cytochrome c
release and activation of BAK and BAX proteins (Ling YH, et. al. 2008).
The tumor suppressor protein p53, known as the “guardian of the genome”, can regulate
the cell cycle and prevent its progression upon recognition of DNA damage or other
cellular insults (Read AP and Stachan T. 1999; Bhana S and Llyod DR. 2008). p53 can
also activate DNA damage repair proteins and can activate cell death cascades if the DNA
damage appears to be irreparable (Offer H, et. al. 2002). It is known that WT cells express
wild-type p53 (Zawacka-Pankau J, et al. 2007). In our studies to determine the mechanism
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of lapatinib resistance, we noted that p53 was over-expressed in WT-AD cells and that the
expression of a transcriptional target of p53, BAX, was lower in these cells compared to
WT cells (Figure 18). It is known that in cancer cells, expression of p53 is often elevated
when it is mutated (Kohler MF, et al. 1992). It was also noted that p53 phosphorylation
was reduced in WT-AD cells compared to WT cells under vehicle as well as lapatinib
treated conditions (Figure 18). This is important since phosphorylation of p53 has been
shown to play an important role in stabilizing and activating p53 so that it can elicit an
appropriate response to cellular stress (Jimenez GS, et. al. 1999). Hence the lack of p53
phosphorylation may suggest that WT-AD cells may be able to avoid activation of cell
death pathways due to lack of appropriate activation of p53. Together, these data suggested
that it was possible that HCT 116 cells expressing a wild-type p53 protein may have
become lapatinib resistant by developing a p53 mutation or by selection of cells already
bearing a p53 mutation. In agreement with this hypothesis, WT-AD cells but not WT cells
expressed a p53 protein that could be immunoprecipitated by an antibody that specifically
recognizes p53 protein mutated in its DNA binding domain (Figure 22). This antibody
differentiates between wild-type and mutant p53 under non-denaturing conditions since a
mutation in the DNA binding domain of p53 can alter its tertiary structure such that it
allows exposure of an epitope that can be recognized by this antibody (Gannon JV, et. al.
1990). This epitope is usually hidden and therefore not exposed to the antibody in the
correctly folded structure of wild-type p53 protein. To further identify whether there
existed a mutation in p53 in WT-AD cells, gene sequencing was performed. However,
upon sequencing the coding regions in the DNA binding domains of p53, no mutations
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were noted in WT-AD cells. This suggests that our antibody was recognizing an alteration
in p53 tertiary conformation in WT-AD cells unrelated to a p53 DNA binding domain
mutation but that was in all likelihood still suppressing p53 function (i.e., reduced BAX
expression) or that p53 mutation had occurred in a domain unrelated to the DNA binding
domain of p53 but that was affecting the tertiary conformation of the DNA binding
domain.
Further studies are required to understand how p53 function, with respect to modulation of
all p53 targets has been altered in lapatinib resistant HCT116 cells.
Next, we wanted to determine whether lapatinib mediated toxicity in WT cells depended
solely on inhibition of ERBB1 and ERBB2 receptors and their downstream pro-survival
pathways. Since lapatinib is thought to mediate its effects by inhibition of ERBB1 and
ERBB2 function, we wanted to mimic this effect using adenovirus-mediated expression of
dominant negative ERBB1 (CD533) and dominant negative ERBB2 (CD572) proteins
(Wood ER, et. al. 2004; Rusnak DW, et. al. 2001). CD533 and CD572 function as
dominant negative ERBB1 and ERBB2 receptors, respectively because they have truncated
C-terminal kinase domains, therefore forming non-functional dimers with wild-type
receptors (Imai K and Takaoka A. 2006; Schmidt-Ullrich RK, et. al. 2003). In spite of
being able to inhibit ERBB1 and ERBB2 receptor phosphorylation similar to lapatinib in
WT cells, the dominant-negative receptors did not recapitulate the toxic effects of lapatinib
in serum-starved WT or WT-AD cells (Figure 23). This suggests that there are possibly
other targets that lapatinib inhibits/interacts with that may play an important role in
inducing toxic effects mediated by lapatinib.
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Since we observed changes in the expression of proteins that act at the mitochondrion to
modulate mitochondrial stability, we next determined whether activation of caspase
proteases played a role in lapatinib toxicity. Caspases are known to activate cell death
pathways by activating pro-apoptotic Bcl-2 family members that can then alter
mitochondrial integrity or vice versa (Gross A, et. al. 1999). Serum-starvation has been
known to induce cell death by activation of caspases (Kilic M, et. al. 2002). Inhibition of
caspase 8 and caspase 9 using IETD and LEHD (inhibitors for the respective enzymes), as
well as using zVAD (a pan-caspase inhibitor), significantly reduced the level of cell death
induced by serum-starvation in WT cells (Figure 24). However, inhibition of caspase 8,
caspase 9 or pan-inhibition of caspase function did not suppress lapatinib toxicity in
serum-starved WT cells (Figure 25). This suggested that lapatinib mediated cell death
involves caspase-independent mechanisms. Since other enzymes such as calpains,
cathepsins and serine proteases have also been implicated in activating cell death
pathways, we wanted to determine whether these factors were involved in lapatinib
mediated cell death (Vandenabeele P, et. al. 2005; Droga-Mazovec G, et. al. 2008; Broker
LE, et. al. 2004). However, inhibiting these enzymes did not significantly protect WT cells
from lapatinib induced cell death, indicating that these enzymes are not prime mediators of
lapatinib toxicity in WT cells (Figure 26, 27).
To investigate caspase-independent mechanisms of lapatinib mediated cell death, we
decided to focus on apoptosis inducing factor (AIF). AIF is normally present in the intermembrane space of the mitochondrion, tethered to the inner mitochondrial membrane
(Otera H, et. al. 2005). In certain stressful situations, AIF is cleaved, released into the
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cytosol upon mitochondrial outer membrane permeablization (MOMP) and it then makes
its way to the nucleus where it can initiate DNA fragmentation (Modjtahedi N, et. al. 2006;
Penninger JM and Kroemer G. 2003). Cell fractionation studies showed that AIF was
released into the cytosol of WT cells treated with lapatinib but a similar increase in
cytosolic release of AIF was not observed in WT-AD cells under the same treatment
conditions (Figure 28). Similar results were observed for cytochrome c although
cytochrome c is typically thought to be involved in caspase-dependent cell death pathways
(Figure 28). However, it has been suggested that cytochrome c release can occur in caspase
independent cell death due to MOMP and this can occur after AIF release because
electrostatic interactions with cardiolipin can retain cytochrome c at the inner
mitochondrial membrane and hence, delay its release (Uren RT, et. al. 2005). Knock-down
of AIF expression in WT cells protected them from lapatinib mediated toxicity and knockdown of AIF expression combined with pan-caspase inhibition further reduced cell death
induced by lapatinib in these cells (Figure 29). These results suggested that AIF is a key
player in lapatinib mediated cell death in WT cells and failure of AIF cytosolic release in
lapatinib treated WT-AD cells possibly protected them from cell death.
Our results show that an alteration in the Bcl-2 family proteins has an important role to
play in mediating lapatinib resistance in HCT 116 cells. Future studies involving Bcl2/Bcl-xl/Mcl-1 antagonists such as obatoclax, combined with lapatinib will need to be
performed in order to determine whether such drugs will enhance the lethality of lapatinib
as well reduce the chances of occurrence of lapatinib resistant cancers. Also, our studies
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suggest that the mechanism of lapatinib mediated toxicity in WT cells may involve effects
of lapatinib on targets other than ERBB1 and ERBB2.
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OBATOCLAX ENHANCES SORAFENIB+HDACI TOXICITY AND
OVERCOMES BLOCKADE OF CD95 PATHWAY TO FACILITATE KILLING
A. Introduction:
The Raf-MEK1/2-ERK1/2 pathway is frequently dysregulated in neoplastic transformation
(Dent P, et. al. 2003; Valerie K, et. al. 2007). The MEK1/2-ERK1/2 module comprises,
along with c-Jun NH2-terminal kinase (JNK1/2) and p38 MAPK, members of the MAPK
super-family. These kinases are involved in responses to diverse mitogens and
environmental stresses and have also been implicated in cell survival processes. Activation
of the ERK1/2 pathway is often associated with promoting cell survival whereas JNK1/2
and p38 MAPK pathway signaling often induces apoptosis. Although the mechanisms by
which ERK1/2 activation promote survival are not fully characterized, a number of antiapoptotic effector proteins have been identified, including increased expression of antiapoptotic proteins such as c-FLIP, Bcl-xl and Mcl-1 and also direct inactivation of proapoptotic proteins such as caspase 9, BAD and BIM (Grant S and Dent P. 2004; Allan LA,
et. al. 2003; Mori M, et. al. 2003; Ley R, et. al. 2003; Wang WF, et. al. 2007; Qiao L, et.
al. 2003). In view of the importance of the RAF-MEK1/2-ERK1/2 pathway in neoplastic
cell survival, inhibitors have been developed that have entered clinical trials, such as
sorafenib (4-[4-[[4-chloro-3-(trifluoromethyl)phenyl] carbamoylamino] phenoxy]-Nmethyl-pyridine-2-carboxamide, Bay 43-9006, Nexavar®; a Raf kinase inhibitor) (Li N, et.
al. 2007). Sorafenib is a multi-kinase inhibitor that was originally developed as an inhibitor
of Raf-1 (c-Raf). Sorafenib occupies the ATP-binding domain of Raf-1 and B-Raf, there
by preventing ATP from binding the kinase (Wan P, et. al. 2004). Subsequently however,
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sorafenib was shown to inhibit multiple other kinases, including platelet-derived growth
factor, vascular endothelial growth factor receptors 1 and 2, c-Kit and FLT3 (14).
Sorafenib is also known to inhibit mutant V559EB-Raf (Wilhelm S and Chien DS. 2002). It
is important to note that sorafenib did not significantly increase cell death in nontransformed cells (Rosato RR, et. al. 2007). Anti-tumor effects of sorafenib in renal cell
carcinoma and in hepatoma have been ascribed to anti-angiogenic actions of this agent
through inhibition of the growth factor receptors (Rini BI. 2006; Gollob JA. 2005).
Sorafenib has also been shown to inhibit tumor cell proliferation and tumor xenograft
growth (Wilhelm SM, et. al. 2004). Previous studies have shown in vitro that sorafenib
kills human leukemia cells at concentrations below the maximum achievable dose (Cmax)
of 15-20 µM, through a mechanism involving down-regulation of the anti-apoptotic Bcl-2
family member Mcl-1 (Rahmani M, et. al. 2005; Rahmani M, et. al. 2007a). In these
studies sorafenib-mediated Mcl-1 down-regulation occurred through a translational rather
than a transcriptional or post-translational process that was mediated by endoplasmic
reticulum stress signaling (Dasmahapatra G, et. al. 2007; Rahmani M, et. al. 2007b).
Hence, previously observed anti-tumor effects of sorafenib are mediated by a combination
of inhibition of Raf family kinases; receptor tyrosine kinases that signal angiogenesis; and
the induction of ER stress signaling.
There are 18 known histone deacetylases (HDACs) in humans and these can be divided
into three classes: Class I include HDAC1, HDAC2, HDAC3 and HDAC8; Class II
include HDAC4, HDAC5, HDAC7 and HDAC9. HDAC6 and HDAC10 belong to Class
IIa and have two catalytic sites. HDAC11 shares characteristics with both Class I and Class
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II and hence is often placed in Class IV. Class III HDACs include sirtuins that require
NAD+ for their activity, lack zinc in their catalytic sites and are not inhibited by commonly
used HDACIs such as vorinostat (suberoylanilide hydroxamic acid, SAHA, ZolinzaTM)
(Dokmanovic M, et. al. 2007; Marks P, et. al. 2001). HDACs, along with histone acetyltransferases (HATs), reciprocally regulate the acetylation status of the positively charged
NH2-terminal histone tails of nucleosomes there by regulating transcription of genes
(Gregory PD, et. al. 2001). HDACs can act not only on histones but on other proteins as
well such as p53. Acetylation of p53 can lead to increased sequence specific binding
activity and hence increased transcription of p53 target genes (Tang Y, et. al. 2008).
HDACs can deacetylate p53 which can decrease the ability of p53 to transcribe target
genes (Glozak MA, et. al. 2005). Alterations in HATs and HDACs have been found in a
variety of cancers. Alterations in expression levels of HDACs have been observed in
certain cancers; however, structural mutations in HDACs are a rare event in cancer cells
(Bolden JE, et. al. 2006; Marks P, et. al. 2001; Dokmanovic M, et. al. 2007). Aberrant
activity of HDACs in cancer cells is often associated with HDACs being recruited by
oncogenic translocation protein complexes (Wilson AJ, et. al. 2006). Histone deacetylase
inhibitors (HDACI) represent a class of agents that act by blocking histone de-acetylation,
thereby modifying chromatin structure and gene transcription. HDAC inhibitors (HDACIs)
promote histone acetylation and neutralization of positively charged lysine residues on
histone tails, allowing chromatin to assume a more open conformation, which favors
transcription (Gregory PD, et. al. 2001). Most HDACIs are thought to function by binding
to the zinc atom in the HDAC catalytic site thereby inhibiting the enzyme’s activity
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(Richon VM. 2006; Taddei A, et. al. 2005). However, HDACIs have also been known to
have plieotropic biological consequences, including inhibition of chaperone HSP90
function (thought to be required for survival of oncogenic fusion proteins), induction of
oxidative injury and up-regulation of death receptor expression (Dasmahapatra G, et. al.
2007; Marks PA, et. al. 2003; Bali P, et. al. 2005; Kwon SH, et. al. 2002).
Vorinostat is a hydroxamic acid HDACI that has shown preliminary pre-clinical evidence
of activity in hepatoma and other malignancies with a Cmax of ~9 µM (Wise LD, et. al.
2007; Zhang G, et. al. 2008). Vorinostat is a pan-inhibitor of HDACs belonging to classes
I and II and has been known to induce growth arrest in a variety of transformed cells
(Marks PA and Breslow R. 2007; Mitsiades CS, et. al. 2004). Vorinostat was also found to
be efficacious in vivo by inhibiting the growth of human cancer xenografts (Marks PA, et.
al. 2005). Vorinostat is known to increase reactive oxygen species (ROS) in cancer cells
but not in normal cells. In addition, vorinostat can increase the levels of thioredoxin
binding protein-2 in cancer cells thereby reducing thioredoxin (known to have ROS
scavenging function) levels and this may facilitate ROS mediated cell death in cancer cells
(Marks PA and Breslow R. 2007). This can explain, at least in part, the relative resistance
to vorinostat toxicity in normal cells and the sensitivity of many cancer cells.
Valproic acid is used as an anti-epileptic drug and also as a mood-stabilizer (Robert E,
1991). It has been known to have teratogenic effects that have now been linked to its
ability to inhibit HDAC activity which is also thought to be responsible for its ability to
inhibit tumor growth, proliferation, angiogenesis, induction of differentiation and
radiosensitization in certain cancer cells (Alsdorf R and Wyszynski DF. 2005; Cinatl J. Jr.,
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et. al. 1997; Duenaz-Gonzalez A, et. al. 2008). Valproic acid administered alone or in
combination with other agents such as cytosine arabinoside, hydroxyurea, cisplatin and
etoposide has been shown to be effective in killing cancer cells (Blaheta RA, et. al. 2005;
Gupta E, et. al. 1997). Valproic acid is a much weaker inhibitor of HDAC activity than
vorinostat and is known to inhibit the function of Class I (1, 2, 3)and Class II (4, 5, 7)
HDACs (Xu W, et. al. 2007; Gurvich N, et. al. 2004).
With respect to combinatorial drug studies with a multi-kinase inhibitor such as sorafenib,
HDACIs are of interest in that they have potential to down-regulate multiple oncogenic
kinases by interfering with HSP90 function, leading to proteasomal degradation of these
proteins. Sorafenib and HDACIs target multiple overlapping downstream signaling
pathways implicated in tumor cell survival. Hence, if combined, there was a possibility
that the two drugs administered together would be more effective than either drug
individually and also that lower doses of these agents may be required to observe toxic
effects on cancer cells. Previous studies have shown that low doses of sorafenib and
vorinostat can act synergistically in a variety of cancer cells (Zhang G, et. al. 2008; Park
MA, et. al. 2008). This drug combination is known to activate the de novo ceramide
synthesis pathway which along with the acidic sphingomyelinase ceramide generation
pathway initiates CD95 death receptor activation. Hence, according to previous studies,
sorafenib and vorinostat mediated cell death is thought to occur via ligand independent but
ceramide dependent activation of the CD95 death receptor signaling pathway and this drug
combination is now entering Phase I clinical trials (Zhang G, et. al. 2008; Park MA, et. al.
2008). It is important to note that previous studies have shown that unlike cancer cells,
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sorafenib and vorinostat combined failed to cause significant cell death in normal bone
marrow cells (Dasmahapatra G, et. al. 2007). Studies have shown that sorafenib interacts
with other HDACI (such as Trichostatin A and sodium butyrate) as well to markedly
increase lethality in cancer cells (Dasmahapatra G, et. al. 2007).
This study investigated whether low dose of sorafenib combined with sodium valproate
(another HDACI, sodium salt of valproic acid) also acted synergistically to kill cancer cells
and whether CD95 death receptor activation had a role to play in mediating cell death
under these conditions.
Several cancers are known to lose CD95 expression/function and this can enable cells to
become resistant to chemotherapeutic agents that utilize the CD95 signaling pathway to
mediate cell death (Ozoren N and El-Deiry WS. 2003; Los M, et. al. 1997; Houston A and
O’Connell J. 2004). Increased expression of mitochondrial protective proteins such as Mcl1 and Bcl-xl have also been implicated in mediating drug resistance in cancer cells (Martin
AP, et. al. 2008; Del Poeta G, et. al. 2008). Since previous studies show that sorafenib and
HDACI combine synergistically to cause cell death via CD95 signaling, it was possible
that in the clinic, resistance to these agents may occur via dysregulation of the CD95
signaling pathway. Hence, it would be logical to combine sorafenib and HDACIs with an
agent that facilitated cell death independent of CD95 by targeting the mitochondrial
protective proteins and could synergize with the two drugs to result in enhanced cell death.
Theoretically, this would reduce the likelihood of tumor cells being inherently resistant as
well as potentially circumventing the development of drug resistant cancers.
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Obatoclax (GX 15-070) is a small molecule antagonist of the BH-3 binding domain of the
Bcl-2 family proteins and is known to mediate its effects in cancer cells independent of the
CD95 pathway via inhibition of Mcl-1-BAK interaction, BIM upregulation and
cytochrome c release into the cytosol (Trudel S, et. al. 2007). Short term toxicity assays
showed that obatoclax has minimal effects on normal human peripheral blood lymphocyte
viability where as significant reduction in cell viability was observed in obatoclax treated
cancer cells (Trudel S, et. al. 2007). Hence, we investigated whether obatoclax enhanced
the toxicity of sorafenib and sodium valproate and whether this three-drug combination
maintained high cell death levels in spite of knock-down of CD95 in cancer cells.
B. Materials:
Sorafenib tosylate was generously provided by Bayer Inc. Vorinostat was generously
provided by Merck & Co., Inc. GX15-070 was generously provided by Gemin X
Pharmaceuticals. Trypsin-EDTA, DMEM, RPMI, penicillin-streptomycin were purchased
from GIBCOBRL (GIBCOBRL Life Technologies, Grand Island, NY). Sodium valproate
was purchased from Sigma. Fetal bovine serum was purchased from hyclone (Logan, UT).
Trypan blue dye and crystal violet were purchased from Sigma-Aldrich. For western blot
analysis, 8-16% gels were used (BIORAD, Carlsbad, CA). HEPG2, HEP3B and PANC1
cells were purchased from the ATCC. Commercially available validated short hairpin
RNA molecules to knock down RNA/protein levels were purchased from Qiagen
(Valencia, CA). Primary antibodies recognizing BAX, BAK, BIM, Mcl-1 and cytochrome
c were purchased from Cell Signaling (San Diego, CA). Primary antibody for active BAK
(Ab-1) was purchased from Calbiochem (San Diego, CA). Primary antibodies for GAPDH,
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active BAX (6A7) and protein A/G plus agarose beads for immunoprecipitation were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Secondary mouse antibody
was purchased from Invitrogen Molecular Probes (Eugene, OR) and secondary rabbit
antibody was purchased from Rockland (Gilbertsville, PA). All siRNAs were pruchased
from Qiagen. C-FLIP-s virus was purchased from Vector Biolabs. DAPI stain was
purchased from Vector Laboratories Inc (Burlingame, CA).

Methods:
Cell Culture: Panc1 pancreatic cancer cells were cultured in DMEM media containing
DMEM media containing 20% fetal bovine serum and 1% Penicillin/Streptomycin.
HEPG2 and HEP3B hepatic cancer cells were culture in MEM Alpha media containing
10% fetal bovine serum and 1% Penicillin/Streptomycin supplemented with sodium
pyruvate, sodium bicarbonate and non-essential amino acids.
Detection of Cell Death by Trypan Blue Assay: After treatment, medium was removed
and cells were washed in 1X PBS. Cells were then harvested by trypsinization with
Trypsin/EDTA for 5 min at 37°C. Because some apoptotic cells detached from the culture
substratum into the medium, these cells were also collected by centrifugation of the
medium at 1400 RPM for 5 min. The pooled cell pellets were resuspended and mixed with
trypan blue dye. Trypan blue stain, in which blue dye-incorporating cells were scored as
being dead, was performed by counting of cells using a light microscope and a
hemacytometer. The number of dead cells was counted and expressed as a percentage of
the total number of cells counted.
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Culture of Cells and Drug Treatments for Colony Formation Assays: Cells were
plated (250–1000 cells/well of a 6-well plate). 12 h after plating medium was removed and
serum-free medium was added to the cells for 24 or 48 h as indicated. After this, the serumfree media was carefully removed and fresh media (with serum) was added. Colony
formation assays were cultured for an additional 8-10 days, after which the media were
removed, cells were fixed with methanol, stained with crystal violet, and counted manually.
Immunoprecipitation and Western Blotting: 12 hours after plating cells, they were
treated with various drugs as indicated. 12, 24 or 48 h after drug treatment, cells were lysed
in whole cell lysis buffer (0.5 M Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 1% βmercaptoethanol, 0.02% bromophenol blue).
12 hours after plating cells, they were treated with drugs as indicated and 24 h after drug
treatment, cells were scraped in CHAPS buffer (10mM HEPES, 140mM NaCl, 1%
CHAPS) and then active BAK, active BAX or Mcl-1 was immunoprecipitated. Samples
were boiled for 10 min in whole cell lysis buffer. All samples were then loaded on 8%16% Criterion pre-cast gels (BIORAD) after normalizing total protein and run for about 2
hours. Proteins were then electrophoretically transferred onto 0.22um nitrocellulose
membranes and immunoblotted with various primary antibodies as indicated.
Virus Infections: Cells were infected 12h after plating with adenoviruses at an
approximate multiplicity of infection of 30 for 4 h with gentle rocking, after which time the
media was replaced. Cells were further incubated for 24 h to ensure adequate expression of
transduced gene products before drug exposures.
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Transfection of Cells with Small Interfering RNA Molecules: RNA interference for
down-regulating the expression of various molecules was performed using validated target
sequences designed by Qiagen. For transfection, 20-40 nM concentration of the annealed
siRNA-targeting Mcl-1, Bcl-xl or Bcl-2, or the negative control (a "scrambled" sequence
with no significant homology to any known gene sequences from mouse, rat, or human cell
lines) were used. The siRNA molecules were transfected into cells according to the
manufacturer's instructions. Cells were cultured for 24 h after transfection before any
additional experimentation.
Cell Fractionation: 12h after plating cells, they were treated with drugs as indicated. 12 or
24 h later, medium from plates was aspirated and cells were scraped in buffer (75mM
NaCl+8mMNa2HPO4+1mMNa2H2PO4+0.5mMEDTA+ 0.5mMEGTA with freshly added
350ug/ml digitonin, 250mM sucrose, protease and phosphatase inhibitor cocktails (Roche))
and passed through a 25 gauge needle 10 times. After 15 to 30 minutes on ice, cells were
spun down at 5000RPM for 1.5 minutes at 4oC to remove cell debris. Pellet was discarded
and supernatant was transferred to a new tube and spun down at 13000 RPM for 25
minutes at 4oC. The supernatant obtained is the cytosolic fraction where as the pellet is the
mitochondrial fraction. Whole cell lysis buffer was added to the supernatant and the pellet,
boiled for 10 minutes and then western blot analysis was performed. This protocol was
adapted from Leist M, et. al. (1998).
CD95 cell surface localization: Cells were washed once in DPBS and fixed with 4%
paraformaldehyde in DPBS. Slides were washed again in DPBS and placed in a humidified
chamber. Blocking solution (1% bovine serum albumin and 2% rat serum in DPBS) was
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added to the cells for 1 hour at room temperature. 1:100 diluted CD95 antibody was then
added to the cells that were then placed in a humidified chamber at 4 degrees Celsius
overnight. The next day, cells were washed once in DPBS and secondary antibody (R-488)
was added diluted 1:300 for an hour. Cells were then washed in DPBS and vectashield
with Dapi stain was added to the cells which were then cover-slipped and read at 100X
magnification.
DAPI staining: Cells were washed once with DPBS and fixed for 20 minutes with 4%
paraformaldehyde (in PBS). Chamber covers were removed from the slides and cells were
washed in DPBS once. Mounting media containing DAPI staining was added to cells and
slides were coverslipped.
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D. Results:
Effect of sorafenib + vorinostat on cell survival and death: Colony formation assays
show that sorafenib and vorinostat act synergistically in Panc1 cells to reduced cell
survival (Table 1). Trypan blue analysis also showed that sorafenib and vorinostat
combination can induce significantly higher levels of cell death compared to vehicle or
individual drug treatments in Panc1 cells (Figure 30), HEP3B cells (Figure 31) and also in
HEPG2 cells (Figure 32).
CD95 pathway in sorafenib + vorinostat induced death: We wanted to confirm previous
studies that showed that sorafenib and vorinostat mediated toxicity occured via CD95
activation (Zhang G, et. al. 2008; Park MA, et. al. 2008). Knock-down of CD95 using
siRNA protected Panc1 cells from sorafenib and vorinostat induced cell death as
determined by trypan blue assay (Figure 33).
c-FLIP-s is a negative regulator of the CD95 pathway and hence, we wanted to investigate
whether over-expression of c-FLIP-s would protect cells from sorafenib and vorinostat
mediated toxicity (Krueger A, et. al. 2001). Results showed that over-expression of cFLIP-s protected Panc1 cells from sorafenib and vorinostat induced cell death as
determined by trypan blue assay (Figure 34). DAPI staining also showed that overexpression of c-FLIP-s protected cells from sorafenib and vorinostat induced DNA
fragmentation (Figure 35).
Effect of sorafenib + sodium valproate on cell survival and death: We wanted to
determine whether sorafenib combined with sodium valproate (also a HDACI) would also
act synergistically to kill cancer cells. For all short term cell viability experiments, we used
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1mM dose of sodium valproate which is a clinically relevant dose (Ueshima S, et. al.
2008). Colony formation assays showed that sorafenib and sodium valproate act
synergistically in Panc1 and HEP3B cells to reduced cell survival (Table 1, 2). Trypan blue
analysis also showed that sorafenib and sodium valproate in combination can induce
significantly higher levels of cell death compared to vehicle or individual drug treatments
in Panc1 and HEPG2 cells (Figure 36, 37).
Mitochondrial translocation of BAX upon sorafenib+sodium valproate treatment: We
next investigated the proteins that may be involved in mediating sorafenib and sodium
valproate toxicity. Cell fractionation studies showed that 12 h after treatment with
sorafenib and sodium valproate combined in HEPG2 cells, BAX translocation from
cytosol to mitochondrial was observed (Figure 38).
BIM and BAK co-immunoprecipitation with MCL-1 in sorafenib + sodium valproate
treated cells: In HEPG2 cells, immunoblotting studies failed to show any significant
change in Mcl-1 expression level 6 h post sorafenib and sodium valproate treatment
(Figure 39). However, at this time-point, immunoprecipitation studies showed that BAK
association with Mcl-1 was decreased in cells treated with the drug combination compared
to vehicle treated cells (Figure 39). 12 h after drug combination treatment, total Mcl-1
expression level as well as levels of BIM and BAK associated with Mcl-1 appeared to be
significantly reduced compared to vehicle treated cells (Figure 39).
CD95 cell surface localization in sorafenib + sodium valproate treated cells: 6 h after
treating HEPG2 cells with vehicle, 3μM sorafenib alone, 1mM sodium valproate alone or
the two drugs together, CD95 cell surface localization was determined (Figure 40). This
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time point was chosen since previous studies have shown that sorafenib and vorinostat
combined result in CD95 cell surface localization/activation as early as 6 h post drug
treatment (Zhang G, et. al. 2008). We observed that 6h after drug treatment, CD95
localization at the cell surface was much greater in HEPG2 cells treated with
sorafenib+sodium valproate compared to other conditions.
Effect of obatoclax in combination with sorafenib alone: We wanted to investigate
whether inhibition of Bcl-2 family members via obatoclax would enhance cancer cell
killing when combined with sorafenib alone. Obatoclax treatment resulted in significantly
higher cell death compared to vehicle treated HEPG2 cells (Figure 41). Obatoclax and
sorafenib combined resulted in significantly higher cell death compared to sorafenib alone
at 3μM and 6μM doses of sorafenib (Figure 41). At all other doses of sorafenib tested, the
presence of obatoclax did not significantly enhance cell death compared to vehicle treated
cells (Figure 41).
Effect of obatoclax in combination with vorinostat alone: We wanted to investigate
whether inhibition of Bcl-2 family members via obatoclax would enhance cancer cell
killing when combined with vorinostat alone. Results showed that obatoclax alone induced
significantly higher cell death in HEPG2 cells compared to vehicle treated cells (Figure
42). Increasing concentrations of vorinostat, alone or in combination with obatoclax, failed
to have a significant effect on cell death compared to respective vehicle treated conditions
(Figure 42).
Effect of obatoclax in combination with sodium valproate alone: We wanted to
investigate whether inhibition of Bcl-2 family members via obatoclax would enhance
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cancer cell killing when combined with sodium valproate alone. In HEPG2 cells, obatoclax
showed significantly higher levels of cell death compared to vehicle treated cells (Figure
43). Increasing concentrations of sodium valproate, alone or in combination with
obatoclax, failed to have a significant effect on cell death compared to respective vehicle
treated conditions (Figure 43).
Effect of obatoclax on sorafenib + sodium valproate mediated cell death: We wanted to
investigate whether inhibition of Bcl-2 family members via obatoclax would enhance
cancer cell killing when administered to cells treated with sorafenib and sodium valproate
simulataneuosly. Trypan blue analysis revealed that there were significant effects of
sorafenib + sodium valproate treatment (at each dose combination tested) and also of
obatoclax on HEPG2 cell death compared to vehicle treated cells (Figure 44). It was also
found that the presence of obatoclax significantly enhanced sorafenib + sodium valproate
induced cell death at each dose combination (Figure 44).
Effect of CD95 knock-down in sorafenib+sodium valproate+obatoclax treated cells:
Knock-down of CD95 in HEPG2 cells protected them from the effects of sorafenib and
sodium valproate alone or in combination and also from obatoclax induced cell death
(Figure 45). However, CD95 knock-down failed to protect HEPG2 cells from death
induced by all three drugs (sorafenib+sodium valproate+obatoclax) in combination (Figure
45).
Effect of c-FLIP-s over-expression in sorafenib+sodium valproate+obatoclax treated
cells: c-FLIP-s over-expression in HEPG2 cells protected them from the effects of
sorafenib and sodium valproate alone or in combination and also from obatoclax induced

96
cell death (Figure 46). However, c-FLIP-s over-expression failed to protect HEPG2 cells
from death induced by all three drugs (sorafenib+sodium valproate+obatoclax) in
combination (Figure 46 ).
Effect of Bcl-xl, Mcl-1 or Bcl-2 knock-down on sorafenib and sodium valproate induced
cell death: To investigate whether obatoclax mediated inhibition of any one Bcl-2 family
member was sufficient to enhance sorafenib+sodium valproate toxicity, HEPG2 cells were
transfected with siRNA to knock-down Bcl-xl, Mcl-1 or Bcl-2 expression and then treated
with vehicle or sorafenib and sodium valproate combined. Trypan blue analysis was then
performed to measure cell viability. Knock-down of Bcl-xl or Bcl-2, but not Mcl-1,
enhanced sorafenib and sodium valproate induced cell death (Figure 47).
Effect of Bcl-xl and Bcl-2 or Bcl-xl, Mcl-1 and Bcl-2 knock-down on sorafenib and
sodium valproate induced cell death: HEPG2 cells were transfected with siRNA to knockdown Bcl-xl and Bcl-2 simultaneously or Bcl-xl, Mcl-1 and Bcl-2 simultaneously and then
treated with vehicle or sorafenib and sodium valproate combined. Trypan blue analysis
was performed to measure cell viability. Compared to siSCR treated cells, simultaneous
knock-down of Bcl-xl and Bcl-2 significantly increased sorafenib and sodium valproate
induced cell death (Figure 48). Simultaneous knock-down of Bcl-xl, Mcl-1 and Bcl-2 also
significantly increased sorafenib and sodium valproate induced cell death compared to
siSCR as well as compared to combined siBcl-xl and siBcl-2 transfected cells (Figure 48).

97
Activation of BAK and BAX: Treatment of HEPG2 cells with sorafenib and sodium
valproate combined, obatoclax alone or sorafenib + sodium valproate + obatoclax
combined resulted in increased BAK and BAX activation compared to vehicle treated cells
suggesting that under these conditions, BAK and BAX are available to initiate cell death
pathways (Figure 49).
Cytosolic release of cytochrome c in cells treated with sorafenib, sodium valproate and
obatoclax: Cell fractionation assays revealed that HEPG2 cells treated with sorafenib +
sodium valproate + obatoclax showed significant release of cytochrome c into the cytosol
and correspondingly, a decrease in the mitochondrial levels of cytochrome c was observed
under the same treatment conditions (Figure 50). These results show that cytosolic
cytochrome c is available to initiate cell death pathways under this condition. Expression
of c-FLIP-s appeared to prevent the release of cytochrome c in these cells under basal and
sorafenib + sodium valproate treatment conditions indicating that blocking the extrinsic
cell death pathway prevents release of cytochrome c under these conditions (Figure 50).
However, in spite of c-FLIP-s over-expression, cytosolic release of cytochrome c was
observed in cells treated with obatoclax alone or sorafenib + sodium valproate + obatoclax
combined (Figure 50). This confirms that in spite of blocking the CD95 pathway, treating
cells with sorafenib + sodium valproate + obatoclax combined can result in cytosolic
cytochrome c release which is then available to activate cell death pathways.
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Sorafenib
(uM)
3.0
6.0
9.0

Vorinostat
(nM)
250
500
750

Sorafenib
(uM)
3.0
4.5
6.0
7.5
9.0

Valproic Acid
(mM)
0.50
0.75
1.00
1.25
1.50

Fa

CI

0.31
0.42
0.51

0.48
0.70
0.83

Fa

CI

0.37
0.43
0.54
0.73
0.80

0.46
0.58
0.57
0.41
0.37

Table 1: Sorafenib synergizes with vorinostat and with sodium valproate in Panc1
cells. 12h after plating Panc1 pancreatic cancer cells, they were treated with vehicle
(DMSO), sorafenib and sodium valproate or vorinostat, as indicated at a fixed
concentration ratio to perform median dose effect analyses for the determination of
synergy. After drug exposure (48h), the media was changed and cells cultured in drug free
media for an additional 10-14 days. Cells were fixed, stained with crystal violet and
colonies of > 50 cells / colony counted. Colony formation data were entered into the
Calcusyn program and combination index (CI) and fraction affected (Fa) values were
determined. A CI value of less than 1.00 indicates synergy and larger the Fa value, the
lower the survival under that condition.
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Figure 30: Sorafenib and vorinostat combined enhance cell death in Panc1 cells. 12 h
after plating Panc1 cells, they were treated with Vehicle (DMSO), 3µM sorafenib, 500nM
vorinostat or 3µM sorafenib and 500nM vorinostat combined. 48 h after drug treatment,
cell viability was measured using the trypan blue exclusion assay ±S.E.M. n=2. One way
ANOVA with Bonferroni post-test revealed that sorafenib and vorinostat combined
induced significantly higher levels of cell death (***, p < 0.0001, n=6) as compared to all
other treatment conditions. Data (mean ± S.E.M.) are from two independent experiments
combined.
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Figure 31: Sorafenib and vorinostat combined enhance cell death in HEP3B cells.
12 h after plating HEP3B hepatoma cells, they were treated with vehicle (DMSO), 3µM
sorafenib, 500nM vorinostat or 3µM sorafenib and 500nM vorinostat combined. 48 or 96 h
after drug treatment, cell viability was measured using the trypan blue exclusion assay.
One way ANOVA with Bonferroni post-test revealed that sorafenib and vorinostat
combined induced significantly higher levels of cell death (***, p < 0.001 at 48 h and **, p
< 0.001 at 96 h, n=6) as compared to all other treatment conditions. Data (mean ± S.E.M.)
are from two independent experiments combined.
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Figure 32: Sorafenib and vorinostat combined enhance cell death in HEPG2 cells.
12 h after plating HEG2 hepatoma cells, they were treated with vehicle (DMSO), 3µM
sorafenib, 500nM vorinostat or 3µM sorafenib and 500nM vorinostat combined. 48 or 96 h
after drug treatment, cell viability was measured using the trypan blue exclusion assay
±S.E.M. n=2. One way ANOVA with Bonferroni post-test revealed that sorafenib and
vorinostat combined induced significantly higher levels of cell death (*, p < 0.05 at 48 h
and ***, p < 0.0001 at 96 h, n=6) as compared to all other treatment conditions. Data
(mean ± S.E.M.) are from two independent experiments combined.
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Figure 33: Knock-down of CD95 protects Panc1 cells from sorafenib+vorinostat
combined lethality. 12 h after plating Panc1 cells, they were transfected with scrambled
siRNA (siSCR) or with siRNA to knock-down CD95 (siCD95). 24 h after transfection,
cells were treated with vehicle (DMSO), 6µM sorafenib, 500nM vorinostat or 3µM
sorafenib and 500nM vorinostat combined. 48 h after drug treatment, cell viability was
measured using Trypan blue exclusion assay. There were significant effects of drug
treatment and knock-down of CD95 on Panc1 cell death (two-way ANOVA, p<0.0001,
n=6). Bonferroni’s post-tests revealed that CD95 knock-down significantly protected
against cell death in the presence of sorafenib and vorinostat combined ( p < 0.001). Data
(mean ± S.E.M.) are from two independent experiments combined.
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Figure 34: Over-expression of c-FLIP-s protects Panc1 cells from sorafenib+
vorinostat comined lethality. 12 h after plating Panc1 cells, they were infected with an
empty vector recombinant adenovirus (CMV) or a virus to express c-FLIP-s. 24 h after
virus infection, cells were treated with vehicle (DMSO), 6µM sorafenib, 500nM vorinostat
or 6µM sorafenib and 500nM vorinostat combined. 48 h after drug treatment, cell viability
was measured using trypan blue exclusion assay ±S.E.M. n=2. There were significant
effects of drug treatment and FLIP expression on Panc1 cell death (two-way ANOVA,
p<0.0001, n=6). Bonferroni’s post-tests revealed that FLIP expression significantly
protected against cell death in the presence of sorafenib or sorafenib and vorinostat
combined ( p < 0.001). Data (mean ± S.E.M.) are from two independent experiments
combined.
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CMV

% apoptotic cells
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Figure 35: Panc1 cells over-expressing c-FLIP-s fail to show nuclear fragmentation
upon sorafenib+vorinostat combined treatment. 12 h after plating Panc1 cells, they
were treated with vehicle (DMSO), 6µM sorafenib, 500nM vorinostat or 6µM sorafenib
and 500nM vorinostat combined. 48 h later, cells were fixed and DAPI staining was
performed using mounting media containing DAPI stain. Apoptosis was measured (50
cells per condition) by expressing the nuclei with obvious DNA fragmentation as a
percentage of DAPI positive nuclei (shown below each panel). Representative study
images from two independent studies shown.
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CI For experimental values Hep3B 48h
Sor
Valproic
Fa
CI
(uM)
(mM)
2.25
0.75
0.12
0.691
3.00
1.00
0.19
0.687
3.75
1.25
0.36
0.540
Table 2: Sorafenib synergizes with sodium valproate to reduce HEP3B cell survival.
12h after plating HEP3B hepatoma cells, they were treated with vehicle (VEH, DMSO) or
sorafenib and sodium valproate, as indicated at a fixed concentration ratio to perform
median dose effect analyses for the determination of synergy. After drug exposure (48h),
the media was changed and cells cultured in drug free media for an additional 10-14 days.
Cells were fixed, stained with crystal violet and colonies of > 50 cells / colony counted.
Colony formation data were entered into the Calcusyn program and combination index
(CI) and fraction affected (Fa) values determined. A CI value of less than 1.00 indicates
synergy and larger the Fa value, the lower the survival under that condition.
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Figure 36: Sorafenib and sodium valproate combined enhance cell death in Panc1
cells. 12 h after plating Panc1 cells, they were treated with vehicle (DMSO), 6µM
sorafenib, 1mM valproate or 6µM sorafenib and 1mM valproate combined. 48 h after drug
treatment, cell viability was measured using the trypan blue exclusion assay. One way
ANOVA with Bonferroni post-test revealed that sorafenib and valproate combined induced
significantly higher levels of cell death (**, p < 0.001, n=6) as compared to all other
treatment conditions. Data (mean ± S.E.M.) are from two independent experiments
combined.

107

25

Percentage cell death

***
20

15

10

3µM Sorafenib+1mM Valproate

1mM Valproate

3µM Sorafenib

0

Vehicle

5

Figure 37: Sorafenib and sodium valproate combined enhance cell death in HEPG2
cells. 12 h after plating HEPG2 cells, they were treated with vehicle (DMSO), 3µM
sorafenib, 1mM sodium valproate or 3µM sorafenib and 1mM sodium valproate combined.
48h after drug treatment, cell viability was measured using trypan blue exclusion assay.
One way ANOVA with Bonferroni post-test revealed that sorafenib and valproate
combined induced significantly higher levels of cell death (***, p < 0.0001, n=6) as
compared to all other treatment conditions. Data (mean ± S.E.M.) are from two
independent experiments combined.
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Figure 38: Mitochondrial translocation of BAX in HEPG2 cells treated with
sorafenib+ sodium valproate combined. 12 h after plating HEPG2 cells, they were
treated with vehicle (DMSO) or sorafenib and sodium valproate as indicated. 12 h after
drug treatment, cell fractionation assay was performed to determine mitochondrial and
cytosolic localization of BAX. Representative image from two independent studies shown.
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Figure 39: BAK and BIM co-immunoprecipitation with Mcl-1 in sorafenib+sodium
valproate combined treated HEPG2 cells. 12 h after plating HEPG2 cells, they were
treated with vehicle (DMSO) or 3µM sorafenib and 1mM sodium valproate as indicated. 6
h or 12 h after drug treatment, Mcl-1 was immunoprecipitated and immunoblotting was
performed to determine levels of BIM or BAK co-immunoprecipitated with Mcl-1.
Representative image from two independent studies shown.
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Figure 40: CD95 cell surface localization in HEPG2 cells treated with sorafenib and
sodium valproate. 12 h after plating HEPG2 cells, they were treated with vehicle,
sorafenib, sodium valproate or sorafenib and sodium valproate combined as indicated. 6 h
post drug treatment, CD95 cell surface localization was performed. Representative images
from one experiment are shown (n=2). Quantitative assessment of increase in fluorescence
intensity was determined from fifty cells counted over two independent experiments.
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Figure 41: Sorafenib dose response in HEPG2 cells with or without obatoclax. 12 h
after plating HEPG2 cells, they were treated with increasing concentrations of Sorafenib as
indicated along with Vehicle or 100nM Obatoclax. 48 h after drug treatment, cell viability
was measured via trypan blue analysis. Two way anova (n=6) shows that there is an effect
of Sorafenib dose (p < 0.0001) and there is an effect of Obatoclax dose (p < 0.0001).
Bonferroni post-test shows that the presence of Obatoclax causes a significant increase in
cell death only under Veh (p < 0.0001) treated or 3 (p < 0.05) and 6 uM (p < 0.0001)
Sorafenib doses compared to identical conditions in the absence of Obatoclax. Data (mean
± S.E.M.) are from two independent experiments combined.
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Figure 42: Vorinostat dose response in HEPG2 cells with or without obatoclax. 12 h
after plating HEPG2 cells, they were treated with increasing concentrations of Vorinostat
as indicated along with Vehicle or 100nM Obatoclax. 48 h after drug treatment, cell
viability was measured via trypan blue analysis. Two way ANOVA (n=6) shows that there
is an effect of Obatoclax dose (p < 0.0001) but no significant effect of increasing doses of
Vorinostat on cell death. Bonferroni’s post-test shows that the presence of Obatoclax
causes a significant increase in cell death under Vehicle treated conditions and also with all
doses of Valproate (p < 0.0001) compared to identical conditions in the absence of
Obatoclax. Data (mean ± S.E.M.) are from two independent experiments combined.
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Figure 43: Sodium valproate dose response in HEPG2 cells with or without obatoclax.
12 h after plating HEPG2 cells, they were treated with increasing concentrations of sodium
valproate (VA) as indicated along with vehicle or 100nM obatoclax. 48 h after drug
treatment, cell viability was measured via trypan blue analysis. Two way ANOVA (n=6)
shows that there is an effect of obatoclax dose (p < 0.0001) but no significant effect of
increasing doses of valproate on cell death. Bonferroni’s post-test shows that the presence
of obatoclax causes a significant increase in cell death under vehicle treated conditions and
also with all doses of valproate (p < 0.0001) compared to identical conditions in the
absence of obatoclax. Data (mean ± S.E.M.) are from two independent experiments
combined.
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Figure 44: Cell death induced by sorafenib+sodium valproate combined in HEPG2
cells with or without obatoclax. 12 h after plating HEPG2 cells, they were treated with
Vehicle (DMSO) or various dose combinations of Sorafenib and Sodium valproate as
indicated with or without 100nM Obatoclax. 48h after drug treatment, cell viability was
measured using trypan blue exclusion assay. There were significant effects of sorafenib +
sodium valproate treatment (at each dose combination tested) and also of obatoclax on
HEPG2 cell death (two-way ANOVA, p < 0.0001 in both cases, n=6). Bonferroni’s posttest revealed that the presence of obatoclax significantly enhanced sorafenib + sodium
valproate induced cell death at each dose combination tested (* p < 0.05, ** p < 0.001, ***
p < 0.0001). Data (mean ± S.E.M.) are from two independent experiments combined.
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Figure 45: Knock-down of CD95 failed to protect HEPG2 cells from obatoclax+
sorafenib+sodium valproate combined lethality. 12 h after plating HEPG2 cells, they
were transfected with scrambled siRNA (siSCR) or with siRNA to knock-down CD95
(siCD95). 24 h after being transfected with siRNA, cells were treated with vehicle
(DMSO), 3µM sorafenib, 1mM valproate or 3µM sorafenib and 1mM valproate combined.
48 h after drug treatment, cell viability was measured in triplicate using trypan blue
analysis. There were significant effects of drug treatment and knock-down of CD95 on
HEPG2 cell death (two-way ANOVA, p<0.0001, n=6). Bonferroni’s post-tests revealed
that CD95 knock-down significantly protected against cell death in the presence of
sorafenib and sodium valproate combined or obatoclax (p < 0.001). Data (mean ± S.E.M.)
are from two independent experiments combined.
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Figure 46: Over-expression of c-FLIP-s failed to protect HEPG2 cells from
obatoclax+ sorafenib+sodium valproate combined lethality. 12 h after plating HEPG2
cells, they were infected with an empty vector recombinant adenovirus (CMV) or a virus to
express c-FLIP-s. 24 h after virus infection, cells were treated with vehicle (DMSO), 3µM
sorafenib, 1mM sodium valproate or 3µM sorafenib and 1mM sodium valproate combined.
48 h after drug treatment, cell viability was measured using trypan blue exclusion assay.
There were significant effects of drug treatment and FLIP over-expression on HEPG2 cell
death (two-way ANOVA, p<0.0001, n=6). Bonferroni’s post-tests revealed that FLIP overexpression significantly protected against cell death in the presence of sorafenib (p < 0.01),
sorafenib and sodium valproate combined or obatoclax (p < 0.001). Data (mean ± S.E.M.)
are from two independent experiments combined.
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Figure 47: Knock-down of Bcl-xl or Bcl-2, but not Mcl-1, enhanced sorafenib+
sodium valproate induced cell death. 12 h after plating HEPG2 cells, they were
transfected with scrambled siRNA (siSCR) or with siRNA to knock-down BclL-xl (siBclxl), Mcl-1 (siMcl-1) or Bcl-2 (siBcl-2). 24 h after transfection, cells were treated with
vehicle (DMSO) or 3µM sorafenib and 1mM sodium valproate combined. 48 h after drug
treatment, cell viability was measure using trypan blue assay. One way ANOVA with Bonferroni’s post test showed that knock-down of Bcl-xl or Bcl-2, but not Mcl-1, enhanced
sorafenib and sodium valproate induced cell death (p < 0.05). Data (mean ± S.E.M.) are
from two independent experiments combined.
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Figure 48: Knock-down of Bcl-xl+Bcl-2 or Bcl-xl+Bcl-2+Mcl-1 enhanced sorafenib+
sodium valproate induced cell death. 12 h after plating HEPG2 cells, they were
transfected with control siRNA (siSCR), siRNA to knock-down Bcl-xl+Bcl-2 or Bclxl+Bcl-2+Mcl-1. 24 h later, cells were treated with vehicle (DMSO) or 3µM sorafenib and
1mM sodium valproate. One way ANOVA with Bon-ferroni’s post test showed that
knock-down of Bcl-xl+Bcl-2 and of Bcl-xl+Bcl-2+Mcl-1 significantly enhanced sorafenib
and sodium valproate induced cell death (p < 0.001) compared to siSCR treated cells. Data
(mean ± S.E.M.) are from two independent experiments combined.
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Figure 49: BAK and BAX activation in HEPG2 cells treated with sorafenib, sodium
valproate and obatoclax. 12 h after plating HEPG2 cells, they were treated with vehicle
(DMSO), 3μM sorafenib and 1mM sodium valproate combined, 250nM obatoclax alone or
all three drugs combined. 24 h after drug treatment, cells were isolated for
immunoprecipitation to determine the amount of the activate BAX and BAK.
Representative images shown (n=2).
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Figure 50: c-FLIP-s over-expression in HEPG2 cells prevents cytosolic cytochrome c
release due to sorafenib+sodium valproate+obatoclax. 12 h after plating HEPG2 cells,
they were treated with vehicle (DMSO), 3μM sorafenib and 1mM sodium valproate
combined, 250nM obatoclax alone or all three drugs combined. 24 h after drug treatment,
cells were isolated for cell fractionation assay to determine cytochrome c release into the
cytosol. A representative from two separate studies is shown.
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D. Discussion:
We have attempted to determine whether sorafenib and sodium valproate interact to kill
transformed cells, and whether obatclax mediated inhibition of mitochondrial Bcl-2 family
protective proteins could enhance sorafenib + sodium valproate toxicity.
The results of the present study indicate that low concentrations of sorafenib and vorinostat
as well as sorafenib and sodium valproate interact in a synergistic manner to kill pancreatic
and liver cancer cells in vitro. Other studies have shown that sorafenib and vorinostat
combined can induce cell death via ligand independent but ceramide dependent activation
of the CD95 death receptor signaling pathway (Zhang G, et. al. 2008; Park MA, et. al.
2008). The CD95 pathway can be negatively regulated by FLIP proteins that have
sequence homology to caspase 8 but lack the catalytic domain and hence when FLIP is
recruited to activated death receptors rather than caspases, it can block activation of the
caspase cascade and the cell death cascade (Krueger A, et. al. 2001). There are several
splice variants of FLIP known to exist at the mRNA levels but three isoforms of FLIP
protein namely, c-FLIP-s, c-FLIP-r and c-FLIP-l have been identified (Djerbi M, et. al.
2001; Rasper DM, et. al. 1998; Golks A, et. al. 2005). This study confirms that sorafenib +
vorinostat induced cell death in cancer cells is mediated via CD95 signaling and shows that
sorafenib + sodium valproate induced lethality in cancer cells also involves CD95
signaling. Knock-down of CD95 or over-expression of c-FLIP-s protected tumor cells
from the effects of these drug combinations. Studies have suggested similar roles of cFLIP-s and c-FLIP-r in death receptor mediated apoptosis (Golks A, et. al. 2005). We
chose to over-express c-FLIP-s rather than c-FLIP-l because studies have confirmed the
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anti-apoptotic role of c-FLIP-s as it can inhibit the activation of pro-caspase 8 and there by
inhibit CD95 induced cell death (Golks A, et. al. 2005). However, the role of c-FLIP-l in
the activation of CD95 pathway remains controversial. Some studies suggest the c-FLIP-l
is an anti-apoptotic molecule where as other studies ascribe pro-apoptotic functions to cFLIP-l referring to its assistance in pro-caspase 8 activation (Chang DW, et. al. 2003;
Micheau O, et. al. 2002). Collectively, the present findings argue that pancreatic and
hepatoma tumor cells are susceptible to being killed by sorafenib + HDACI exposure
through a death receptor dependent mechanism.
Studies have shown that anti-apoptotic Bcl-2 family proteins namely, Bcl-xl and Mcl-1
play a role in maintaining mitochondrial integrity and prevent activation of cell death
pathways (Certo M, et. al. 2006; Chipuk JE and Green DR. 2008). In unstressed cells, proapoptotic Bcl-2 family protein BAK has been shown to be sequestered primarily by Mcl-1
(Cuconati A, et. al. 2003). Upon death receptor and caspase 8 activation, BH-3 only
protein BID is cleaved to form truncated BID (tBID) which is known to displace BAK
from the Mcl-1-BAK complex allowing BAK to perform its pro-apoptotic functions
(Clohessy JG, et. al. 2006). We observed that 6 h after sorafenib and sodium valproate
treatment, no significant change in Mcl-1 level is observed compared to control treated
cells. However, at this time point after sorafenib and sodium valproate combined
treatment, a decrease in BAK association with Mcl-1 is observed suggesting that BAK is
available to activate cell death pathways as early as 6 h post sorafenib and sodium
valproate combined treatment. 12 h post sorafenib and sodium valproate treatment, a
decrease in Mcl-1 level as well as a decrease in BIM co-immunoprecipitated with Mcl-1 in
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observed. Studies have shown that in unstressed cells, BIM is sequestered by Mcl-1 and
certain stressful stimuli can lead to caspase mediated degradation of Mcl-1 and this allows
Mcl-1-free BIM to initiate cell death pathways (Han J, et. al. 2006).
It is known that the pro-apoptotic Bcl-2 family protein BAX primarily resides in the
cytosol of unstressed cells and upon certain stressful stimuli, BAX is known to translocate
to the mitochondria where it can damage mitochondrial integrity and initiate cell death
pathways (Murphy KM, et. al. 2000). We found that sorafenib and sodium valproate
combined induce mitochondrial localization of BAX within 12 h of treatment suggesting
that upon exposure to the drug combination, BAX translocates to the mitochondria in order
to initiate cell death pathways.
Studies have shown that in cancer cells HDACI alone can induce CD95 activation and
sorafenib and vorinostat combined can cause an increase in CD95 cell surface
localization/activation 6 h post drug treatment (Insinga A, et. al. 2005; Zhang G, et. al.
2008). Our results showed that 6 h after drug treatment, neither sorafenib nor sodium
valproate alone induced CD95 cell surface localization but this was observed in cells
treated with both drugs at the same time suggesting that the drug combination is able to
activate CD95 cell death pathway as early as 6 h after treatment. This also indicates that
CD95 activation is likely invovled in mediating cell death induced by sorafenib and
sodium valproate combination treatment.
An inability to express death receptors or the ability to over-express dominant negative
forms of death receptors has been linked to apoptosis resistance (Walsh CM, et. al. 2003;
Safa AR, et. al. 2008). An additional mechanism that could block toxic death receptor
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signaling is constitutive high expression levels of c-FLIP-s (Safa AR, et. al. 2008).
Increased expression of mitochondrial protective proteins such as Mcl-1 and Bcl-xl have
also been implicated in mediating drug resistance in cancer cells (Martin AP, et. al. 2008;
Del Poeta G, et. al. 2008). As mentioned previously, our studies show that sorafenib +
HDACI combined can trigger cell death via CD95 signaling. We wanted to enhance the
toxicity of sorafenib and sodium valproate combined, as well as reduce the chance of
resistance development in cancer cells treated with these agents. Therefore, it was logical
to combine sorafenib and sodium valproate with obatoclax, which can facilitate cell death
independent of CD95 signaling, target the mitochondrial protective proteins, and according
to our results, obatoclax can enhance cell death in cancer cells when combined with
sorafenib and sodium valproate at all dose combinations tested. Theoretically, using these
three drugs in combination would reduce the likelihood of tumor cells being resistant as
well as potentially circumventing the development of drug resistant cancers. We found that
while knock-down of CD95 or over-expression of c-FLIP-s, protected tumor cells from
sorafenib and sodium valproate combined lethality, additional treatment of cells with
obatoclax under these conditions failed to protect them from cell death. This confirmed our
hypothesis that treating cancer cells with obatoclax+sorafenib+sodium valproate induces
cell death that is maintained even upon blockade of CD95 signaling.
No significant effect on cell death was found upon addition of obatoclax to cells co-treated
with varying doses of vorinostat or sodium valproate. The presence of obatoclax, however,
caused a significant increase in cell death when combined with 3 uM and 6 uM sorafenib
compared to identical conditions in the absence of obatoclax. However, cell death was
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enhanced most when obatoclax was combined with sorafenib and sodium valproate
simultaneously.
As mentioned previously, obatoclax is a pan-inhibitor of the protective Bcl-2 family
proteins which includes Bcl-xl, Mcl-1 and Bcl-2 (Trudel S, et. al. 2007). Since obatoclax
enhanced sorafenib and sodium valproate mediated cell death, we determined whether
knock-down of Bcl-xl, Mcl-1 or Bcl-2 alone would be sufficient to mimic the effects of
obatoclax on sorafenib and sodium valproate treated cells. siRNA mediated individual
knock-down of Bcl-xl or Bcl-2 , but not Mcl-1, significantly enhance sorafenib and sodium
valproate induced cell death compared to control siRNA treated cells. Simultaneous knock
down of Bcl-2 and Bcl-xl significantly increased sorafenib + sodium valproate toxicity
compared to control siRNA treated cells. Furthemore, simultaneous loss of Bcl-2, Bcl-xl
and Mcl-1 expression resulted in a significant increase in sorafenib + sodium valproate
induced cell death compared to control siRNA and siBcl-xl + siBcl-2 treated cells. This
suggests that inhibiting more than one pro-survival Bcl-2 family protein at the same time,
rather than individual Bcl-2 family members, enhances sorafenib and sodium valproate
mediated lethality to a greater extent.
Studies have shown that in the presence of cellular stress, BAK and BAX change
conformation, oligomerize and form pores in the outer mitochondrial membrane that
allows the release of proteins from the inter-mitochondrial space that can then activate cell
death pathways (Antignani A and Youle RJ. 2006). Immunoblotting studies showed that
compared to vehicle conditions, treatment of cells with sorafenib + sodium valproate
combined, obatoclax alone or sorafenib + sodium valproate + obatoclax combined resulted
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in increased “active” BAK and BAX proteins suggesting that in the presence of the above
mentioned drug treatments, BAK and BAX are activated and hence available to initiate cell
death pathways.
Upon activation, pro-apoptotic Bcl-2 family proteins BAK and BAX can lead to the
release of cytochrome c from the mitochondria to cytosol (Wei MC, et. al. 2001; Desagher
S, et. al. 1999). This is considered a key step in the initiation of cell death pathways as this
can lead to formation of the apoptosome consisting of cytochrome c, its adaptor molecule
called Apaf-1 (apoptotic protease activating factor 1) and pro-caspase 9 (Cain K, et. al.
2000). Binding of cytochrome c to Apaf-1 is thought to facilitate the binding of ATP to the
apoptosome which then allows for caspase 9 activation (Adrain C, et. al. 1999). Active
caspase 9 can then lead to activation of various other caspases including caspase 2, 3, 6, 7,
8 and 10 (Guerrero AD, et. al. 2008).Cells treated with sorafenib + sodium valproate +
obatoclax simultaneously show a higher level of cytochrome c release into the cytosol as
compared to other treatment conditions. Over-expression of c-FLIP-s abolishes basal and
sorafenib + sodium valproate induced cytosolic release of cytochrome c. However, in spite
of c-FLIP-s over-expression, cytosolic release of cytochrome c is observed in cells treated
with either obatoclax alone or treated with sorafenib + sodium valproate + obatoclax
combined. This indicates that cell death pathways can be activated via cytosolic release of
cytochrome c in cells treated with sorafenib + sodium valproate + obatoclax in spite of loss
of CD95 function mediated by c-FLIP-s over-expression.
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As sorafenib+HDACI therapy is about to be explored in a phase I trial, our data suggest
that the incorporation of obatoclax together with sorafenib+HDACI therapy may provide
significant additional value in tumor control.
In conclusion, the results of the present study indicate that sorafenib and vorinostat or
sodium valproate interact in a synergistic manner to kill pancreatic and liver tumor cells in
vitro via activation of CD95. These effects are magnified when Bcl-2 family protein
activity is inhibited and of novelty demonstrate that loss of extrinsic pathway activation
does not diminish cell death levels induced by sorafenib and sodium valproate in
combination with obatoclax.
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GENERAL DISCUSSION

We investigated the mechanism of lapatinib mediated cell death and lapatinib resistance in
HCT 116 colon cancer cells. Lapatinib has been approved by the Food and Drug
Administration to be used in the treatment for breast cancer as part of a combination
therapy. Clinical trials have been planned and are underway to investigate the use of
lapatinib in the treatment of other types of cancers including colorectal cancer
(Clinicaltrials.gov). Hence, it is important to understand the mechanism of action of
lapatinib in order to optimize its toxic effects on cancer cells and also identify other drugs
that may be combined with lapatinib to enhance cancer cell killing and reduce occurrence
of refractory cancers. Lapatinib has been known to cause its effects by inhibiting ERBB1
and ERBB2 tyrosine kinase receptors and their downstream signaling pathways (Wood
ER, et. al. 2004; Rusnak DW, et. al. 2001). We expressed dominant negative ERBB1
and/or ERBB2 receptors in wild-type HCT116 colon cancer cells in order to mimic the
effects of lapatinib and to investigate whether inhibition of these receptors was the sole
mechanism of lapatinib mediated toxicity in these cells. Dominant negative ERBB1 and
ERBB2 receptors were able to inhibit receptor activation similar to lapatinib but were
unable to induce comparable levels of cell death as seen in the presence of lapatinib. It is
possible that CD533 and CD572 inhibit the receptors but are unable to inhibit downstream
ERK and Akt activation Hence, we determined whether an inability to inhibit ERK1/2 and
Akt pro-survival signaling pathways prevented CD533 and CD572 from inducing of cell
death in WT cells. However, dominant negative ERBB1 and ERBB2 receptors inhibited
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ERK1/2 and Akt phosphorylation in WT cells indicating that lack of inhibition of these
pro-survival signaling pathways was not the reason for lack of cell death in cells treated
with CD533 and CD572. This data suggests that lapatinib mediated effects in wild-type
HCT 116 cells may not solely depend on inhibition of ERBB1 and ERBB2 pathways and
that possibly other targets of lapatinib are involved. Several drugs have been developed to
target specific, however, over the years, studies have shown that these agents can mediate
their toxicity by inhibition of other target molecules as well. For instance, sorafenib was
developed as a Raf-kinase inhibitor but later studies showed that it could mediate its
effects via inhibition of other kinases such as VEGFR and PDGFR (Wilhelm SM, et. al.
2008). Hence, it is possible that further studies may reveal other targets of lapatinib.
The present study showed that lapatinib induced cell death in wild-type HCT 116 cells is
caspase independent and is mediated by cytosolic release of apoptosis inducing factor
(AIF) from the mitochondria which is thought to initiate cell death (Penninger JM and
Kroemer G. 2003). Other chemotherapeutic agents have also been known to induce cell
death via AIF activation. For instance, studies show that arsenic trioxide is effective in
killing human cervical cancer cells via cytosolic release of AIF (Kang YH, et. al. 2004).
Chemotherapeutic drug resistance development has been shown to be a major problem in
the process of treating cancer (Kobayashi S, et. al. 2005). Initial drug treatment may kill
cancer cells but often times cells may become resistant to drugs used to treat the cancer
initially and also to a variety of other chemotherapeutic agents making it refractory cancers
very difficult to manage (Kobayashi S, et. al. 2005). Our studies show that it is possible for
lapatinib resistance to occur in colon cancer cells. This suggests that lapatinib resistance
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could occur in patients and understanding the mechanism of lapatinib resistance in colon
cancer cells may enable us to diagnose and treat resistance development in the clinic. It
may also assist us in designing combinatorial therapy regimes in order to reduce the
chances of lapatinib resistance development in cancer patients.
Other studies have shown that in breast cancer cells, lapatinib resistance can occur due
alterations in the PI3K pathway via loss-of-function mutations in the tumor suppressor
PTEN, up-regulation of estrogen receptor or due to an inabililty of lapatinib to inhibit prosurvival ERK and Akt signaling downstream of ERBB receptors (Eichhorn PJ, et. al. 2008;
Chen FL, et. al. 2008; Zhou H, et. al. 2004). However, in WT-AD cells, it was observed
that inhibition estrogen receptor signaling did not restore lapatinib sensitivity in these cells
suggesting that lapatinib resistance in WT-AD cells was unlikely to be mediated by
changes in estrogen receptor signaling. Studies performed by others in our laboratory have
also shown that inhibition of ERK1/2 and/or Akt in WT-AD cells did not enhance lapatinib
mediated cell death suggesting that these proteins were not responsible for lapatinib
resistance in WT-AD cells (Martin AP, et. al. 2008).
In WT-AD cells, increased expression Bcl-xl, Mcl-1 and p53 proteins, decreased
expression of pro-death Bax protein and decreased phosphorylation of p53 was noted. It
was also found that Bax and Bak proteins were activated in lapatinib treated wild-type
HCT 116 cells but not in WT-AD cells. Hence, it appears that alterations in the expression
and activation of Bcl-2 family proteins are involved in mediating lapatinib resistance in
HCT 116 colon cancer cells. Other studies have shown that altered expression of Bcl-2
family proteins can confer multi-drug resistance phenotype in cancer cells by dramatically
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reducing toxicity mediated by commonly used therapeutic agents such as bleomycin,
cisplatin and etoposide (Raffo AJ, et. al. 1995; Minn AJ, et. al. 1995). Hence, several
drugs have been developed to target Bcl-2 family proteins such as obatoclax that mimics
the BH-3 domain of pro-death Bcl-2 family members and can inhibit the activity of prosurvival Bcl-2 members by interacting with them (Zhang L, et. al. 2007).
Further studies will be required to investigate the effects of Bcl-2 family inhibitors on WT
and WT-AD cells but it can be expected that such inhibitors will prove to be toxic to
lapatinib resistant WT-AD cells. If this is the case, it may prove beneficial to combine
lapatinib with a Bcl-2 family inhibitor such as obatoclax in the clinic in order to reduce the
likelihood of resistance development in patients.
Our studies confirmed previous finding that multi-kinase inhibitor sorafenib and vorinostat
(a histone deacetylase inhibitor or HDACI) combined toxicity is mediated via CD95 death
receptor pathway (Zhang G, et. al. 2008; Park MA, et. al. 2008). We have also shown that
sorafenib interacts with another HDACI named sodium valproate in a synergistic manner
to kill transformed cells via a mechanism involving the CD95 death receptor pathway.
Studies have shown that HDACIs themselves can cause an induction of the CD95/CD95L
system and hence cells treated with HDACI alone may also show elevated CD95 surface
localization/activation (Glick RD, et. al. 1999). However, at the time-points tested, we
found that CD95 cell surface localization was elevated in cells treated with sorafenib and
sodium valproate combined but not in cells treated with vehicle or individual drugs.
Previous studies have shown that in cancer cells, resistance to drugs that mediate their
effects via the CD95 pathway can occur due to an inability of the cells to express death
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receptors or by over-expressing dominant negative forms of death receptors (Park SM, et.
al. 2005; Walsh CM, et. al. 2003). Since sorafenib+HDACI mediated effects involve
CD95 activation, it is possible that alterations in the CD95 signaling pathway may render
cancer cells resistant to this drug combination. Hence, we wanted to combine sorafenib and
sodium valproate with a third agent i.e. obatoclax. Obatoclax mediated cell death is CD95
independent and therefore combining it with sorafenib+sodium valproate may reduce
chances of resistance development occurring due to alterations in the CD95 signaling
pathway. Obatoclax is a BH-3 mimetic and binds the BH-3 binding domain of the Bcl-2
family proteins and is known to mediate its effects in cancer cells via inhibition of Mcl-1BAK interaction, BIM upregulation and cytochrome c release into the cytosol (Trudel S,
et. al. 2007). Alterations in the Bcl-2 family proteins have also been implicated in
mediating chemotherapeutic drug resistance in cancer (Martin AP, et. al. 2008) and based
on previous, using obatoclax may likely reduce occurrence of resistance development in
cancer cells via alterations in the Bcl-2 family proteins as well (Nguyen M, et. al. 2007).
Results showed that obatoclax enhanced the toxicity of sorafenib and sodium valproate
combined. Knock-down of CD95 or over-expression of c-FLIP-s (a negative regulator of
the CD95 pathway) to mimic a non-functional CD95 pathway, protected cells from
sorafenib+sodium valproate mediated cells death. However, no significant reduction in cell
death levels was found in HEPG2 hepatoma cells treated with all three agents (i.e.
sorafenib+sodium valproate+obatoclax) in spite of CD95 knock-down or over-expression
of c-FLIP-s. This confirmed our hypothesis that combining sorafenib and sodium valproate
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with obatoclax (which is known to mediate cell death independent of CD95 activation)
maintains toxic effects in cancer cells even if the CD95 pathway is not functional.
In conclusion, the results of the present study indicate that sorafenib and vorinostat or
sodium valproate interact in a highly synergistic manner to kill tumor cells in vitro via
activation of CD95 pathway. These effects are magnified as well as maintained in spite of
loss of CD95 death receptor pathway function when Bcl-2 family protein activity is
inhibited in addition to sorafenib+sodium valproate treatment of HEPG2 liver cancer cells.
This suggests that it may prove beneficial to combined sorafenib+HDACI with a Bcl-2
family inhibitor such as obatoclax in order to avoid occurrence of refractory cancers in
patients.
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